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Abstract 
Mycobacterium tuberculosis kills approximately two million people each year and is second 
only to HIV/AIDs in terms of death from infectious disease. The most pertinent problem in 
regards to Mycobacterium tuberculosis today is the increasing prevalence of drug resistant 
strains. Thus, there is a great need for the development of new drugs with novel targets. 
This thesis aimed to address this problem by synthesizing a compound that could exploit 
the mycothiol detoxification pathway, unique to Mycobacterium, in order to cause cell 
death, through the release of a harmful halothioketene.  
Synthetic Target
Mycothiol Detoxifaction
Pathway
β-Lyase
Halothioketene
 
The research described herein involved the successful synthesis of the desired mycothiol 
analogue, along with three other related compounds. The target compounds were 
synthesised via protection of N-acetyl glucosamine, followed by thioglycosidation with 
cyclohexane thiol. Subsequent deprotection and coupling to Boc protected S-
trichlorovinyl cysteine provided access to the synthetic target and its β-anomer, as well as 
their Boc protected precursors.  
The original synthetic target demonstrated weak antimycobacterial activity against 
Mycobacterium smegmatis and an encouraging sub 100 µM MIC against Mycobacterium 
bovis derived Bacillus Calmette–Guérin.  Unexpectedly the beta anomer of the synthetic 
target also displayed antimycobacterial activity against Bacillus Calmette–Guérin (MIC 125 
- 250 µM).  All compounds proved to be active against HL60 cells (16-114 µM).   
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Whilst further work is required to improve efficacy, the work presented here 
demonstrates the potential of these compounds as leads for the generation of new 
antimycobacterial agents.   
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Chapter 1 
1. Introduction 
The aim of this thesis is to explore whether the mycothiol pathway, in combination with 
cysteine conjugate β-lyases, could be exploited in order to activate a prodrug to produce 
an accumulation of harmful halothioketenes selectively in Mycobacterium Tuberculosis. 
This should ultimately result in cell death and thus provide a novel target and mechanism 
of action for the treatment of tuberculosis. 
 
1.1 Mycobacterium tuberculosis 
 
1.1.1 Epidemiology 
 
Mycobacterium tuberculosis is the major causative agent for tuberculosis (TB). TB is 
primarily an infection of the lung, although it may be localized elsewhere, particularly in 
immunocompromized people. Clinical symptoms include fatigue, anorexia, weight loss, 
fevers and potentially death1.  On a worldwide basis there are an estimated eight  million 
new cases of TB each year, of which approximately two million are lethal; making it second 
only to HIV/AIDs in terms of deaths from an infectious disease2.  
There are two possible outcomes that occur upon infection by Mycobacterium tuberculosis: 
Less frequently, the host will develop the clinical symptoms associated with the disease 
(active TB). Alternatively, which is more often the case, the immune system will control and 
isolate the pathogen, progressing to what is known as latent TB. This state represents a 
stalemate between the host's immune system and the Mycobacterium tuberculosis, where 
the pathogen population is not able to actively grow, nor is the immune system able 
completely eradicate the pathogen3. It is estimated that approximately one third of the 
world's population is infected with latent TB. These people will not exhibit any clinical signs 
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of TB, nor are they contagious. However they may at any time progress to its active form. 
The probability of this occurring is estimated at between two and twenty three percent 
over a lifetime, with the risk of it occurring increasing in diabetic, malnourished or 
immunocompromized people, as well as though drug use and in cancer sufferers4.  
 
1.1.2 Current Treatment  
 
1.1.2.1 Vaccines 
 
Prevention can be a very effective form of treatment and with this in mind, an effective 
vaccine would represent a great step forward in the fight against Mycobacterium 
tuberculosis. However, although there are a large number of potential vaccines being 
explored in human clinical trials, there is only one vaccine currently in use, namely bacille 
Calmette–Guerin (BCG)5, 6. Despite being the world's most widely administered vaccine, 
BCG is a long way from being optimal and carries with it some significant drawbacks7. BCG's 
major drawbacks  are its highly variable efficacy and its inefficiency in preventing TB in 
adolescents and adults8. Thus, although vaccines may represent an ideal solution for the 
control of TB, there is currently no reliable vaccine available. Therefore the use of 
antibiotics in the treatment of tuberculosis remains pertinent.   
 
1.1.2.2 Antibiotics 
 
The current TB treatment regime recommended by the world health organization involves 
treatment with a combination of four of the first line TB drugs. These drugs include 
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and Thioacetazone. After an initial two 
month treatment patients should continue treatment with Isonazid in combination with 
either Rifampicin and/or Ethambutol for a further four to six months. The combination of 
drugs used and the time they are used for is dependent on factors such as the severity of 
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the infection, whether it is a reoccurring infection, or whether the patients has a 
concomitant HIV infection2. Patients in which Mycobacterium tuberculosis is resistant to 
the first line drugs, can be given second line drugs. However, these drugs often come with 
major drawbacks, such as decreased efficacy and more severe side effects2.  The treatment 
complexity, time required and multitude of drugs needed demonstrates just how difficult 
TB is to treat.  This difficulty stems from the perseverance of drug resistant strains of 
Mycobacterium tuberculosis. 
 
1.1.3 Drug Resistance 
 
1.1.3.1 Phenotypic Resistance 
 
Mycobacterium tuberculosis possesses many mechanisms that lead to drug resistance. 
From a phenotypic perspective, Mycobacterium tuberculosis has a highly impervious cell 
wall that confers resistance to the vast majority of available antibiotics9. Resistance is 
further exacerbated by its ability to reside in multiple metabolic states. In the latent form 
described above (section 1.1.1) the Mycobacterium tuberculosis lies in a dormant, non 
replicating state. This causes problems, as current antibiotics against TB are most effective 
when the Mycobacterium tuberculosis is actively replicating10.  While they provide inherent 
resistance to a wide range of antibiotics, these phenotypes are not the reason for one of 
the biggest health concerns in regards to TB today. Instead it is the increasing prevalence 
of Mycobacterium tuberculosis that possess genetic resistance to the drugs currently used 
to treat TB, i.e. multi and extensive drug resistant TB.  
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1.1.3.2 Genetic Resistance 
 
As many as 440,000 cases of multidrug resistant TB strains were estimated to have occurred 
in 200811 and continued to rise at an alarming rate, reaching 605,000 by 201012. Doctors 
using inadequate treatment regimes and failure of patients to adhere to the regimes that 
are adequate has added to an increase in multi and extensive drug resistance to TB over 
the past decade. The multi drug resistant strains demonstrate resistance to the common 
first line drugs Isoniazid and Rifampicin. Extensive drug resistant strains "exhibit resistance 
to Rifampicin and Isoniazid, any fluoroquinolone, and one of the three injectable drugs, 
Capreomycin, Kanamycin, and Amikacin" 11..  
Resistant strains in Mycobacterium tuberculosis are a direct result of spontaneous 
mutations that occur on its genome. Hence, these resistant strains can develop in any 
population and, over time, drug based selection pressures can cause growth in the resistant 
strain to the point where it represents the largest  portion of Mycobacterium tuberculosis 
present in the host11. It is because of this phenomenon that multiple drugs are required to 
treat TB and why incorrect treatment strategies can quickly cause a proliferation in 
multidrug and extensive drug resistant strains.   
Multi and extensive drug resistant strains of TB are of serious concern. Although treatment 
is available, they pose problems due to their increased costs and fatality rates. Recently 
there has been incidence of a strain resistant to all forms of tuberculosis drugs13. With drug 
resistance to tuberculosis becoming more prevalent, the search for new treatments to 
combat the disease becomes more pertinent. 
 
1.1.4 Future Treatment Targets 
 
The need for new and novel TB treatments has increased interest and research in the area, 
with anti-TB drugs in clinical and preclinical trials currently at its highest point in 40 years12. 
Advancements made in drug screening has led to the identification of a plethora of new 
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compounds that exhibit high levels of toxicity toward Mycobacterium tuberculosis. 
Between 2006 and 2011 alone, 278 natural products and their derivatives have been found 
that have a minimum inhibitory concentration (MIC) of less than 50 µg/mL against 
Mycobacterium tuberculosis or the closely related Mycobacterium smegmatis14. However 
there is a high attrition rate in the progression of these compounds into clinical evaluation.  
At the time of writing, there are only ten drugs in clinical development (table 1.1). Of these 
just six drugs are novel, while three have been repurposed from other disease treatments 
to test their viability against TB. The remaining one is currently being re-evaluated to see if 
its efficacy can be enhanced 9, 12, 15.  
The small number of anti-TB drugs currently in clinical development demonstrates the need 
for a sustained effort in the development of new drugs to combat TB. Of particular 
importance are drugs that work through novel targets and metabolic pathways. These 
drugs will have a higher chance of success against drug resistant strains as well as a 
decreased risk of drug-drug interactions10. One such pathway that meets this criteria is the 
mycothiol pathway and for this reason much interest has been generated by considering 
the mycothiol pathway in Mycobacterium tuberculosis 16-18.  
 
 
Table 1.1. Anti-TB Drugs Currently in Clinical Trials 
 
Drug 
Novel 
Compound 
Phase of Clinical Trial Chemical Class 
PA-824 Novel 2 Nitroimidazole-oxazine 
Sutezolid Novel 2 Oxazolidinone 
Bedaquiline Novel 2 Diarylquinoline 
SQ109 Novel 2 Ethylenediamine 
Linezolid Repurposed 2 Oxazolidinone 
Rifapentine Re-evaluated 2 and 3 Rifamycin 
AZD5847 Novel 2 Oxazolidinone 
Gatifloxacin Repurposed 3 Fluoroquinolone 
Moxifloxacin Repurposed 3 Fluoroquinolone 
Delamanid Novel 3 Nitro-dihydro-Imidazoooxazole 
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1.2 Mycothiol  
 
1.2.1 Mycothiol Structure 
 
Mycothiol is the major low molecular weight thiol found in the majority of actinomycetes; 
the most clinically relevant of these being Mycobacterium tuberculosis. It was not 
discovered until 1993, when Fahey et al. were able to determine its existence in a range of 
actinomycetes. However they could not fully characterise its structure, with the only thing 
known about it at that time being that it contained cysteine 19. Since then it has been 
demonstrated that its structure is composed of an N-acetylated cysteine linked through an 
amide bond to glucosamine, which itself is linked to myo-inositol through a glycosidic bond 
(Figure 1.1)20.  
 
1.2.2 Role of Mycothiol  
 
Mycothiol performs a role analogous to that of the other low molecular weight thiols found 
in a range of organisms. These include glutathione which is found in eukaryotes and gram 
negative bacteria, trypanothione in trypanosomatids and coenzyme A in certain gram 
positive bacteria19. The discovery of mycothiol came quite late in comparison to its 
eukaryotic relative glutathione.  
 
Figure 1.1. Structure of Mycothiol 
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However, in the two decades since its discovery a large quantity of research has been 
undertaken, that provides a great wealth of knowledge in regards to its roles and functions. 
The vast majority of mycothiol-containing actinomycetes do not produce any glutathione, 
suggesting that mycothiol acts as a direct replacement to glutathione in actinomycetes. 
Thus, as with glutathione, the main roles of mycothiol are: 1) regulation of the redox 
potential in the cell in order to maintain a reducing environment and 2) protecting the cell 
against dangerous electrophilic radicals and xenobiotics21. Consequently, due to the 
important roles mycothiol plays in mycobacteria there has been a large amount of interest 
in mycothiols biosynthetic and metabolic enzymes as potential drug targets for 
Mycobacterium tuberculosis. Several of these enzymes have been researched to determine 
their viability as potential targets. The key ones are described below. 
 
1.2.3 Targeting Mycothiol 
 
1.2.3.1 Mycothiol Biosynthesis 
 
There are in total five enzymes involved in the biosynthesis of mycothiol from its N-acetyl 
glucosamine precursor. They include MshA1 and MshA2, which together are responsible 
for joining the inositol and N-acetyl glucosamine together. Once joined MshB removes the 
N-acetate from the glucosamine, allowing MshC to conjugate the cysteine portion. The final 
step in the biosynthesis is the addition of an acetate group to the cysteine amine by MshD, 
resulting in the completed mycothiol. Of these enzymes, MshA1 and MshC are essential to 
the growth of Mycobacterium tuberculosis. Disrupting the genes encoding for either of 
these enzymes causes no mycothiol to be produced and consequently prevents 
Mycobacterium tuberculosis from growing22.  
 
In one study, Newton et al. (2006) screened  2024 compounds looking for MshC inhibition, 
and discovered a compound, termed NTF1836, that has an IC50 = 100 µM against MshC. 
NTF1836 was able to completely inhibit the growth of Mycobacterium smegmatis at 40 µM. 
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However, the activity may not be a direct result of MshC inhibition, as Mycobacterium 
smegmatis has been demonstrated to grow in the absence of MshC, suggesting NTF1836 
has an alternative target as well23.  Nevertheless, the importance of MshA1 and MshC 
enzymes to Mycobacterium tuberculosis suggests a potent inhibitor of either enzyme would 
be a good candidate for an anti-TB drug.  
 
1.2.3.2 Mycothiol Disulfide Reductase 
 
One of mycothiol's most important roles is to prevent damage from harmful free radicals 
and oxidants by maintaining a reducing environment inside the cell. To achieve this 
mycothiol will react with free radicals and oxidants, subsequently causing their reduction 
as well as the oxidation of mycothiol to its corresponding disulphide mycothione (Figure 
1.2). In order to maintain the reducing environment the mycothione needs to be reduced 
so as to replenish the mycothiol. This is achieved via an NADPH-dependent flavoprotein, 
mycothiol disulfide reductase (Mtr). Studies have shown that antisense oligonucleoside 
inhibition of Mtr in Mycobacterium bovis results in a reduction of growth. However, it will 
not stop growth completely24. Thus Mtr may not be a viable anti-TB drug if it is directly  
  
 
Figure 1.2. Structure of Mycothione 
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targeted. Nonetheless, it is known that majority of antibiotics used result in a build up of 
toxic hydoxyl free radicals, regardless of the drug's target. These hydroxyl free radicals are 
a major contributor to cell death. Thus, by combining traditional drugs with drugs that 
inhibit the cell's defence against free radicals, i.e. Mtr in Mycobacterium tuberculosis, it may 
be possible to synergistically enhance the efficacy of existing antibiotics25. 
                                                        
1.2.3.3 Mycothiol S-Conjugate Amidase 
  
Mycothiol S-conjugate amidase plays an important role in the detoxification of harmful 
electrophilic xenobiotics in actinomycetes. Mycothiol will conjugate electrophilic 
xenobiotics through its cysteine sulphur. The newly formed conjugate is subsequently 
cleaved by mycothiol S-conjugate amidase (Mca), releasing the conjugated N-acetylated 
cysteine (mercapturic acid) from the inositol and glucosamine rings (GlcN-Ins). The 
mercapturic acid is then readily excreted from the cell and GlcN-Ins is recycled back into 
mycothiol's biosynthetic pathway21. Mca has a broad substrate scope in regards to what is 
conjugated to the cysteine sulphur. Variations range from large to small and polar to non 
polar, although small and polar compounds, such as mycothiol itself, show substantially 
reduced activity26.  This substrate scope can be best exemplified by the different antibiotics 
Mca is able to metabolise. Substrates range from the large, macrocyclic and complex 
Rifamycin, to the comparatively small Cerulenin21.   
 
The inhibition of Mca has been the focus of a number of studies. Over 1500 compounds 
have been tested for their activity against Mca, a number of which have IC50's less than 10 
µM16, 27. These studies and the other studies performed to date on mycothiol's other 
biosynthetic and metabolic enzymes have all been explored for inhibition in order to 
develop anti-TB drugs. The reasoning behind the focus on inhibition is due to the fact that 
mycothiol has been shown to be essential to the survival of the Mycobacterium tuberculosis 
and as it is not present in humans, its metabolic and biosynthetic enzymes provide a good 
entry point into the development of  selective drugs against TB13.  However, there is another 
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approach that warrants consideration. This is to use one of mycothiol's metabolic 
pathways, namely Mca detoxification, in the selective killing of mycobacterium tuberculosis 
through the use of halogenated alkenes. 
   
1.3 Halogenated Alkenes 
 
1.3.1 Halogenanted Alkene Toxicity 
 
1.3.1.1 Halogenated Alkenes and their Uses 
 
Of the simplest forms of halogenated alkenes, i.e. haloethenes, tetrachloroethylene and 
trichloroethylene are the most widely used due to their lipophilicity and non-flammability 
as solvents. These  properties make them useful in roles such as degreasing metals and dry 
in cleaning fabrics28. In the 1930's, trichloroethylene was even used as a general 
anaesthetic. Neither tetrachloroethylene or trichloroethylene occur naturally in nature, 
though due to their wide spread use they are found as common contaminants in both air 
and drinking water. As of 1995 an estimated 34% of America's drinking water was thought 
to be contaminated with trichloroethene, a figure that would presumably be larger today28.  
 
1.3.1.2 Discovery of Toxicity 
 
It was not until over 20 years after its first use as a general aesthetic that toxicity relating 
to haloalkene exposure was first proposed. This hypothesis manifested out of an 
observation that calves fed trichloroethylene-extracted soybeans had a high rate of aplastic 
aneamia29. It was later suggested by McKinney et al. (1959) that the cause of the aplastic 
ameamia was a metabolic product of trichloroethylene, namely 1,2-dichlorovinyl cysteine 
(DCVC)30. The discovery came about through the observation that the administration of 
DCVC to calves caused the same aplastic anaemia syndrome that was seen in the calves fed 
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trichloroethylene-extracted soybeans30.  There is still much debate around the toxicity and 
carcinogenicity of halogenated alkenes, trichloroethylene in particular. A lot of ambiguity 
and scepticism exists in the studies done to date, both in animals and humans28.  
 
1.3.1.3 Animal studies and Human studies on Toxicity and Carcinogenicity 
 
Since  the initial studies on aplastic anaemia in calves there have been numerous studies 
looking at the toxicity of trichloroethylene in both animals and humans, particularly in 
regards to its carcinogenicity. In 1995, on the back of evidence obtained from animal 
studies, the International Agency for Research on Cancer (IARC) deemed there was 
"sufficient evidence" to conclude that trichloroethylene does display carcinogenicity in 
animals. The experiments included four inhalation experiments on mice, all of which 
indicated an increase risk in various tumours. Rats and hamsters were also tested with 
varying results31. Given that trichloroethylene displayed some carcinogenicity in certain 
animal models the question remained as to whether the same carcinogenicity would be 
seen in humans. Most of the case studies into humans have considered people exposed to 
trichloroethylene at high levels. These studies tend to show a small but statistically 
significant increase in the amount of urinary proteins and other markers for 
nephrotoxicity32. Further, multiple studies have demonstrated an increase in the risk of 
contracting renal cancer in people exposed to high levels over a number of years. However, 
these studies have been criticized due to perceived methodology flaws. Nevertheless, the 
evidence obtained does suggest a weak correlation between high level trichloroethylene 
exposure and renal cancer in humans32.    
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1.3.2 Halogenated Alkene Metabolism 
  
1.3.2.1 Detoxicification Routes 
 
In order to gain a better understanding of trichloroethylene toxicity, multiple studies have 
been performed looking at the metabolic fate of trichloroethylene in human and animals. 
The results of these studies found the majority of trichloroethylene is metabolized by 
cytochromes P450 to trichloroethanol, trichloroethanol-glucuronide and trichloroacetic 
acid.  Nonetheless, it is thought that the toxicity caused by trichloroethylene is not a direct 
result of any of the metabolites formed from cytochrome P450 metabolism33. Instead the 
main culprit is believed to occur through glutathione metabolism. The amount of 
trichloroethlyene that gets metabolized through this pathway is extremely low, estimated 
to be less than 0.01% of the total dose of trichloroethylene in humans. However this small 
percentage is sufficient to cause damage, due to the high toxicity of some of the 
metabolites that are produced during this glutathione metabolism34.   
 
1.3.2.2 Glutathione Metabolism  
 
As mentioned previously (section 1.2.2), glutathione acts in an analogous manner to 
mycothiol. As such, one of its more important roles is in the detoxification of harmful 
electrophilic xenobiotics19. There is conclusive evidence that glutathione-mediated 
metabolism of trichloroethylene does occur. Both human and animal studies have isolated 
metabolic products consistent with glutathione metabolism present in urine after exposure 
to trichloroethylene35, 36. Upon entry into the cell, trichloroethylene is processed by 
glutathione S-transferases (GSTs) to the corresponding glutathione S-conjugate, which gets 
metabolized further by γ-glutamyltransferase and various dipeptidases to form DCVC33. 
Unlike trichloroethylene and tetrachloroethylene there is no doubt that DCVC is toxic; a fact 
that has been proven in numerous studies37-39. In the case of trichloroethylene metabolism 
DCVC can lead to either detoxification or toxicity. Detoxification occurs via N-acetylation of 
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cysteine's amine. This step is catalysed by amino acylases producing a non-toxic 
mercapturic acid which is rapidly excreted from the cell40. However, without N-acetylation 
the DCVC's free amine allows metabolism through an alternative route. This route is 
catalysed by β-Lyases and results in the formation of extremely toxic metabolites41.  
 
1.3.3 Cysteine Conjugate β-Lyases 
 
1.3.3.1 Distribution and Discovery 
 
The name β-lyases is given to a set of enzymes that catalyse the cleavage of the cysteine S-
conjugates through the sulphur-carbon bond of cysteine, in a β-elimination reaction40. This 
reaction was first demonstrated to occur in DCVC by Bhattacharya et al. (1967)42. 
Nonetheless, it was not until 1978 that the term "cysteine conjugate β-lyase" was first 
used43.  There are currently thirteen enzymes containing cysteine conjugate β-lyase activity 
that have been identified in mammals, eight of which are cytosolic and five of which reside 
in the mitochondria44. These -lyases are particularly prevalent in the kidney and liver, 
which explains why much of the toxicity associated with trichloroethylene exposure is 
isolated to the kidney45. The primary role of enzymes that exhibit cysteine conjugate β-lyase 
activity is not the beta elimination reaction they are usually characterized by, rather the 
majority of them are amino acid transferases44. Amino acid transferases are found widely 
throughout nature, including in bacteria and as such β-lyases should be prevalent in 
bacteria as well. A study by Dekant et al. (1986) supports this as it demonstrated Salmonella 
typhimurium have a significantly higher β-lyase concentration than mammalian cells46. 
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1.3.3.2 Cysteine S-Conjugate Metabolism by β-Lyases 
 
Both the β-elimination and transamination reactions require pyridoxal 5'-phosphate (PLP) 
as a coenzyme. The transamination reaction results in the conversion of an amino acid to 
it's corresponding α-ketoacid. In this reaction, the PLP will be converted to pyridoxamine 
5'-phospahate (PMP). In this form the enzyme is unable to catalyze a β-elimination reaction, 
though may be converted back to its PLP form through the reverse reaction, i.e. conversion 
of α-ketoacid to amino acid44. Thus, the addition of α-ketoacid can increase β-lyase 
mediated toxicity by converting the inactive PMP to PLP, allowing β-elimination to take 
place47.  As mentioned above, the β-Lyases catalyse the cleavage of the C-S bond of cysteine 
through a β-elimination reaction. The β-elimination reaction performed by β-lyases 
ultimately results in the production of pyruvate, ammonia and a halothioalkene (Figure 
1.3). It is this halothioalkene that is associated with the toxicity of trichloroethylene and 
various other halogenated alkenes45.  
 
1.3.4 Halothioalkene Toxicity 
 
The toxicity of the halothoialkenes  are a direct result of their propensity to undergo 
transformation into a number of highly reactive intermediates including tautomerization to 
form thionyl acyl chlorides, or the loss of a halogen to form halothioketenes48. The 
halothioketenes in particular have been shown to be highly toxic. Volkel et al. (1998) 
demonstrated the high reactivity of halothioketenes, namely chlorothioketenes, by 
showing under optimal conditions chlorothioketenes could react with DNA, though had a 
higher propensity toward reacting with proteins49. Halothioketenes are also capable of 
β-Lyase
 
Figure 1.3. β-lysis of cysteine-S-conjugate 
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reacting with the cell’s glutathione, causing subsequent depletion of the cell’s glutathione 
stores, resulting in oxidative stress and lipid peroxidation, ultimately leading to cell death50. 
Due to their inherent toxicity, halothioketenes could provide a novel approach to the 
treatment of TB, provided they can be made to specifically target the pathogen and avoid 
release in human cells. Utilizing mycothiol metabolism present in Mycobacterium 
tuberculosis provides an opportunity to induce the same halothioketene toxicity that is 
seen in mammals exposed to trichloroethylene. 
 
1.4 Mycothiol Induced Toxicity 
 
1.4.1 Mycothiol and Glutathione Pathway 
       
As stated previously (section 1.2.3.3 and 1.3.2.2), both Mycobacterium tuberculosis and 
mammals utilize low molecular weight thiols to detoxify harmful electrophilic xenobiotics. 
In mammals glutathione will conjugate the electrophile to its cysteine's sulphur. The 
glutathione conjugate will then undergo metabolism by a number of enzymes to produce 
the corresponding cysteine S-conjugate. This can then either get N-acetylated to produce a 
non-toxic mercapturic acid, or alternatively, β-elimination can take place resulting in the 
production of a harmful halothioketene. In comparison, Mycobacterium tuberculosis 
utilizes mycothiol to detoxify electrophilic compounds21. This method of detoxification is 
more efficient than the glutathione based system. The reason being that the cysteine in 
mycothiol is already N-acetylated, thus once a electrophile is conjugated to the mycothiol 
it requires just one enzyme, Mca, to produce the same end product of glutathione 
metabolism, i.e. a mercapturic acid.  
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1.4.2 Subverting the Mycothiol Pathway 
 
Because mycothiol metabolism is not present in mammals it  provides an opportunity to 
selectivity release halothioketenes into Mycobacterium tuberculosis. However some of the 
differences between the detoxification pathways could pose problems. The end product of 
both their detoxifications is mercapturic acid, which excretes the conjugated electrophile 
out of the cell. The key difference in the two systems in terms of haloalkene toxicity is the 
N-acetylatation of cysteine. This occurs in the last step of mercapturic acid formation in the 
glutathione pathway, while is present before conjugation in the case of the mycothiol 
pathway20. The activation and release of the toxic halothioketene is dependent on the 
cysteine not being acetylated so β-elimination can occur. Thus, the halothioketene if 
conjugated to mycothiol would not released40. Taking this into consideration, the structure 
of a proposed mycothiol analogue (Figure 1.4) is suggested as a possible carrier for selective 
release of toxic haloalkenes in Mycobacterium tuberculosis.   
1.4.3 Proposed Mechanism for Conjugated Mycothiol Analogue 
 
The proposed mechanism for the analogue causing Mycobacterium tuberculosis death is as 
follows:  Upon entry into the mycobacterial cell, the analogue is recognized by Mca and 
subsequent cleavage of the amide bond occurs. This results in the release of the cysteine 
S-conjugate. The conjugate is then cleaved by -lyases and the haloalkene sulfur fragment 
13
 
Figure 1.4. Proposed structure of conjugated mycothiol analogue 
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is released. The unstable haloalkene sulfur fragment then converts to a halothioketene and 
this results in the binding and disruption of macromolecules, as well as potentially reacting 
with the mycothiol, resulting in oxidative stress and a decrease in cell viability.  
                                                  
1.5 Structure Design 
 
The proposed structure above (Figure 1.4) was based on an analogue produced by Knapp 
et al. (2002). However, it differs in two key areas; 1) the removal of the N-acetyl group from 
the cysteine and 2) the conjugation of the cysteine sulphur with a haloalkene.  
 
1.5.1 Cysteine N-Acetylation and Hydroxyl Removal 
 
The mycothiol analogue proposed by Knapp et al. (2002) had good activity for Mca, around 
half of what is observed with mycothiol (MSH), indicating  that the simplification of the 
inositol ring by the removal of hydroxyl groups should not be too detrimental to its 
activity18. However, the removal of the N-acetyl group to allow for β-elimination to take 
place will have a greater effect on Mca recognition and activity. Newton et al. (2000) 
investigated the effect of removing the N-acetyl group from the cysteine and found a 
significant decrease in the activity of Mca toward the substrate, with it showing just 0.1% 
of the activity shown by the N-acetylated mycothiol20, 51. Furthermore, a later study noted 
that the mycothiol biosynthetic enzyme MshB, which cleaves the N-acetyl amide bond of 
GlcN-inositol (section 1.2.3.1), demonstrated a 500% increase in activity toward the same 
des-N-acetyl substrate than it's native GlcN-inositol substrate. Thus, removal of the N-
acetate from cysteine may not cause a significant decrease in the amide cleavage of the 
proposed mycothiol analogue20, 51. The other structural variation on mycothiol and the 
analogue developed by Knapp et al. (2002) is the conjugation of the haloalkene18.  
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1.5.2 Cysteine-S-Conjugate Selection 
 
1.5.2.1 Haloalkene Selection 
 
The haloalkene initially chosen is tetrachloroethene, which would produce S-(1,2,2-
tricholorvinyl)-L-cysteine (TCVC) upon cleavage by Mca. Birner et al. (1997) looked at the 
toxicity of TCVC, S-(1,2-dichlorovinyl)-L-cysteine, S-(2,2-dichlorovinyl)-L-cysteine and S-
(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine (PCBC) in rat kidneys and found that TCVC 
produced the greatest amount of damage to the kidney cells41. This result suggests TCVC 
should be effective in disrupting the viability of the Mycobacterium tuberculosis and avoids 
the problem of regioselectivity that would be seen with trichloroethylene.  
 
1.5.2.2 Fluorescent Tag Selection 
 
A compound containing a fluorescent tag (Figure 1.5) was chosen to be synthesized 
alongside the compound seen in (Figure 1.4) in order to track cell entry and enzymatic 
activity. Tracking of mycothiol is typically done with the use of monobromobimane. Bimane 
is a fluorophore that gets conjugated to cysteine of mycothiol in the same way as the 
haloalkenes.  The bimane conjugate has been shown to elicit the highest activity towards 
Mca to date, making it ideal for the tracking of the mycothiol detoxification pathway21.  The 
application of the bimane conjugate's use in tracking the activity of the substrate with Mca 
was demonstrated by Knapp et al. (2002). They used fluorescence-detected HPLC to detect 
the mycothiol conjugate with bimane, and its corresponding mercapturic acid, 
demonstrating the potential to use monobromobimane in the study of the proposed 
mycothiol analogue uptake and degradation18.  
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1.6 Chemical Synthesis of Mycothiol 
 
1.6.1 Past Syntheses of Mycothiol 
 
In past studies involving mycothiol, two approaches are taken to obtaining mycothiol. They 
are whole cell extraction and chemical synthesis. Mycothiol is a difficult compound to 
isolate through whole cell extracts; it takes 1 litre of Mycothiol smegmatis cell culture to 
produce just 1.5 mg of mycothiol. In many cases this method is impractical, especially when 
a scale up is required21. It is therefore not surprising that a lot of effort has been dedicated 
in to producing mycothiol through chemical synthesis.  
 
There have been a number of mycothiol syntheses to date, which from a synthetic view 
point contain many challenging structural features. These include α/β selectivity at the 
anomeric centre, avoiding racemisation when conjugating cysteine, as well as 
desymmetrisation and protection of the inositol52-54. The first synthesis of mycothiol was 
developed by Bornemann et al. (1997)54. It required a cumbersome five step 
protection/deprotection sequence to produce the appropriately protected insitol . Once 
formed, this functionalized inositol was coupled to a derivatized glucosamine in a silver 
 
Figure 1.5. Structure of proposed fluorescent mycothiol analogue 
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triflate mediated reaction. Sixty percent of the conjugated adduct was obtained in a 1:1 
mixture of α/β anomers. This synthesis was in fact a semi-synthesis utilizing a undialysed 
Mycothiol smegmatis cell extract in the final step of their synthesis to conjugate the 
cysteine and GlcN-Inositol. The final step resulted in a 40% yield containing both mycothiol 
and its des-acetyl cysteine analogue in a 4:1 mixture respectively54.  A later synthesis was 
developed by Lee et al. (2004)53. They employed an Me3SiOTf-promoted coupling of a 
trichloroacetimidate functionalized glucosamine and derivatized inositol, resulting in a 9:1 
(α:β) ratio in a 45% yield. The conjugation of the GlcN-Inositol to N-acetyl cysteine however 
proved problematic, with both carbodiimide coupling reagents EDCI and DCC resulting in 
racemization. Nonetheless a diastereomerically pure product was achieved using  
HATU/HOAt and collidine, though a poor yield of 21% was obtained 53. The two syntheses 
outlined above demonstrate some of the key structural challenges in regards to mycothiol 
synthesis. A number of other syntheses have also been completed13, 52, 55.  However, none 
of these have managed to synthesise mycothiol on a scale that could not be easily reached 
via whole cell extracts and thus a higher yielding and more scalable synthesis was 
required21.  
 
1.6.2 Knapp et al. (2002) Synthesis of a Mycothiol Analogue  
  
Knapp et al. (2002) bypassed the problem of low yielding mycothiol syntheses by producing 
a mycothiol analogue (Scheme 1.1) that is biologically active toward Mca and can be readily 
synthesized in large quantities. The compound itself can be synthesized in seven steps from 
β-glucosamine pentaacetate. The synthesis involves the formation of a thiazoline through 
treatment of β-glucosamine pentaacetate with Lawesson's reagent, followed by the 
opening of the thiazoline with TFA to yield an anomeric α-mercaptan. Conjugating of a 
cyclohexane ring was achieved through an AIBN-induced radical reaction between 
cyclohexene and the mercaptan. Subsequent acetate deprotection using hydrazine 
afforded a GlcN-Inositol derivative. By stripping the hydroxyls of the inositol and using a 
sulphur linker, the issue of α/β selectivity was solved and the need for cumbersome 
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protection/deprotection to obtain the properly derived inositol was removed.  The 
production of the mycothiol derivative was achieved by coupling the GlcN-Inositol 
derivative to N-Boc-S-Acetyl cysteine using EDCI, followed by TFA treatment to remove the 
Boc protecting group. The use of a Boc protecting group allowed no racemisation to take 
place during conjugation, despite the use of the carbodiimide coupling reagent EDCI. 
Treatment of the coupled product with pyridine caused acetate transfer from the sulphur 
to nitrogen, resulting in the formation of the mycothiol analogue (Scheme 1.1). The overall 
yield of this synthesis was 53%, significantly greater than the other syntheses of mycothiol. 
Therefore the compound synthesized by Knapp et al. (2002) will be the starting point in 
regards to the synthesis of the mycothiol analogue described herein.  
1.6.3 Synthetic Plan for this Study 
 
 
1. Pyridne
2. Sephadex
100%
24 hr, 120°C, 84%
100%
EDCI, DMF, 82%
Lawesson's Reagent
Toluene, N2, 2 hr, 80°C
TFA, MeOH, H2O
rt, 2 hrs, 100%
AIBN, Cyclohexene, THF
N2, 7 hr, reflux, 79%
NH2NH2.H2O, 
TFA, 100%
 
Scheme 1.1. Knapp et al. (2002) synthesis of a simplified mycothiol analogue18 
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Knapp's (2002) synthetic strategy will provide the basis from which the desired compounds 
will synthesized. The proposed synthesis of both the haloalkene and bimane derivitives can 
be seen in schemes 1.2 and 1.3. The cysteine derivatives will be synthesized firstly by Boc 
protection of the L-cysteine's amine with di-tert-butyl dicarbonate forming N-Boc cysteine 
2. The N-Boc cysteine can then be conjugated through cysteine's sulphur to either 
tertrachloroethylene, forming N-Boc-TCVC 3, or monobromobiamane, forming the bimane 
derivative 4. The formation of 5-10 will follow Knapp's synthesis. However the synthesis will 
deviate from this point in regards to the derivatization added at cysteine's sulphur, though 
will stay true to Knapp's coupling conditions employing EDCI in DMF producing coupled 
products 11 and 12. As well the deprotection of Boc using TFA to yield products 13 and 14 
as the desired mycothiol analogues. 
 
 
 
 
1
2
3
4
NaHCO3(aq), Boc2O, THF
N2, rt, overnight
N2, rt, 1hr
C2Cl4, Acetonitrile, DBN
NaHCO3(aq)
Monobromobimane
rt, 3 hr
 
Scheme 1.2. Proposed synthesis of the cysteine-S-conjugates 
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EDCI, DMF
R1= 
R2=
5 6
7
8
9
10
11 = R = R1
12 = R = R2
13 = R = R1
14 = R = R2
Ac2O, NaOAc
1 hr, 100 °C
Lawesson's Reagent
Toluene, N2, 2 hr, 80°C
TFA, MeOH, H2O
rt, 2 hrs
AIBN, Cyclohexene, THF
N2, 7 hr, reflux
NH2NH2.H2O, 24 hr, 120°C
TFA
 
Scheme 1.3. Proposed synthesis of mycothiol analogues 13 and 14 
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1.7 Research Objectives 
 
The thesis described herein set out to determine whether the mycothiol detoxification 
pathway, present Mycobacterium tuberculosis, can be exploited, in conjugation with β-
lyases, to cause a build-up of harmful halothioketenes and subsequent cell death.   To this 
end, the major aim was the synthesis and biological evaluation of mycothiol analogue 13.  
The objectives required to achieve this aim were: 
1) Synthesis of N-Boc-TCVC 
2) Synthesis of the simplified GlcN-Inositol 10 
3) Conjugation of fragments made from objectives 1 and 2 and deprotection to form 13 
4) Synthesis of fluorophore 14 to evaluate cell entry 
5) Synthesis of the β-anomer of 13 (became an objective part way through thesis, for 
reasons discussed in chapter 3)     
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Chapter 2  
2. Cysteine Derivative Synthesis 
One of the overarching goals in this thesis was the synthesis of the mycothiol analogue 13, 
for which, the formation of N-Boc-TCVC represents an important objective.  This chapter 
outlines the successful synthesis of N-Boc-TCVC, through N-Boc protection of L-cysteine and 
subsequent tetrachloroethylene conjugation.  
 
2.1 Boc Protection of L-Cysteine 
 
2.1.1 Reduction of N-Boc-L-Cystine 
 
Based on previous literature, the N-Boc protection of L-cysteine was thought to be 
obtainable through treatment of L-cysteine with di-tert-butyl dicarbonate under alkaline 
conditions56, 57. However, these conditions promoted the production of both the desired N-
Boc-L-cysteine and its oxidized form N-Boc-L-cystine (Scheme 2.1).  This reaction mixture 
was subjected to sodium borohydride reducing conditions in an attempt to reduce the 
unwanted N-Boc-L-cystine into the desired N-Boc-L-cysteine58. Based on 1H NMR evidence, 
a portion of the N-Boc-L-cystine was reduced, however, a significant quantity still remained. 
In order to gain a better indication of the effectiveness of this reaction, L-cystine was doubly 
1
15
2
Base(aq), Boc2O, THF
rt, overnight
 
 Scheme 2.1. Attempted synthesis of N-Boc-L-cysteine 
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protected with di-tert-butyl dicarbonate to afford N-Boc-L-cystine in 93% yield after 
isolation56. The newly obtained N-Boc-L-cystine was then reacted with a larger excess of 
sodium borohydride in an attempt to push the reaction to completion. Once again this 
resulted in only partial reduction. With sodium borohydride unable to promote the 
complete reduction of N-Boc-L-cystine, an alternative literature method was examined 
using zinc and acetic acid in ether (Table 2.1)59.  The first attempt resulted in no reduction 
occurring at all, which was put down to a lack solubility in diethyl ether. With this in mind, 
the subsequent reaction employed THF as the solvent, in which cysteine demonstrated 
much better solubility. This resulted in a partial reduction of N-Boc-L-cystine, 
demonstrating solubility as the probable culprit for the failure of the first attempt. On the 
basis of another literature method, which demonstrated that a temperature of up to 60 °C 
could be used without causing the deprotection of Boc protecting groups, a higher 
temperature was applied in order to promote the complete reduction (Reaction 3)60. This 
involved initially cooling the reaction to 0 ºC then allowing it to warm up to room 
temperature over a 1 h period, followed by an additional 3 hrs at room temperature. This 
resulted in the complete reduction of the N-Boc-L-Cystine to the desired N-Boc-L-Cysteine. 
However, this set of reaction conditions proved unreliable, with the subsequent two 
reduction attempts resulting in complex reaction mixtures.  
Table 2.1. Optimization of Zinc Mediated N-Boc-L-Cystine Reduction 
Reaction Reagents Quantity Time  Temperature 
Level of 
Reductiona 
1 Boc-Cystine 447 mg    
 Zinc dust 3.29 g 2 hr 0 °C Partial 
  5% Acetic acid in Diethyl ether 17 mL       
2 Boc-Cystine 376 mg     
 Zinc dust 2.75 g 2 hr 0 °C Partial 
  5% Acetic acid in THF 14 mL       
3 Boc-Cystine 270 mg     
 Zinc dust 2.27 g 4 hr 0 °C up to 20 °C Inconsistentb 
  5% Acetic acid in THF 10 mL       
aDetermined from 1H NMR. bThis reaction resulted in 100 % reduction in first attempt, however subsequent 
attempts yielded complex mixtures 
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2.1.2 Minimising N-Boc-L-Cystine Formation 
 
In order to bypass problems associated with the reduction of N-Boc-L-cystine, an effort was 
made to minimize  the isolation of N-Boc-L-cystine following the protection of L-cysteine. 
Variations in the reaction time, base used and number of equivalents of L-cysteine were 
investigated (Table 2.2). It was hypothesised that by shortening the reaction length the 
formation of N-Boc-L-cystine may be minimized (provided that the rate of L-cystine 
formation was significantly lower than the rate of the Boc protection of cysteine). This did 
prove to be the case, with these reaction conditions providing a reduction in the amount of 
N-Boc-Cystine formed. However, because the reaction was stopped prior to completion, 
there was also a corresponding decrease in yield.   
It was also hypothesized that the use of excess cysteine, relative to di-tert-butyl 
dicarbonate, should ensure that the majority of the oxidized L-cystine is present in either 
the unprotected or incompletely Boc-protected form. The vast majority should therefore 
remain in the aqueous layer (Figure 2.1). Based on this theory, 4 equivalents of L-cysteine 
were used, relative to di-tert-butyl dicarbonate, as expected this resulted in an increase in 
the N-Boc-L-cysteine to N-Boc-L-cystine ratio, such that N-Boc-L-cysteine represented the 
major product. Like the reaction involving a shorter reaction time, a decrease in combined 
yield was observed. It is important to note that in both cases the quantity of N-Boc-L-
cysteine obtained remained constant. Thus, the decrease in combined yield is entirely due 
to a substantial decrease in the amount of N-Boc-cystine formed.   
Table 2.2. Optimization of L-Cysteine Boc Protection 
Reaction Time (hrs) Cysteine (eq) Nitrogen  Base 
Boc-Cysteine : 
Boc-Cystinea 
Yieldb 
1 18 1 Yes  NaOH  42 : 58 87% 
2 3 1 Yes  NaOH 62 : 38 57% 
3 30 4 Yes  NaOH 59 : 41 59% 
4 18 4 Yes  NaHCO3   95 : 5   56% 
aDetermined by 1H NMR. bCombined yield of Boc-cysteine and Boc-cystine  
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Gratifyingly, almost no N-Boc-L-cystine was isolated when sodium bicarbonate was used 
with 4 eq. of L-cysteine, producing the desired N-Boc-L-cysteine in 66% yield.  
 
2.2 Cysteine S-Conjugation  
 
The initial plan for the synthesis of N-Boc-TCVC 3 was to utilise methodology by Bartels and 
Miner (1990) to synthesise trichlorovinyl cysteine (TCVC)61, then subsequently protect the 
amine with a Boc protecting group to afford compound 3. This sequence was initially 
undertaken due to the propensity of cysteine to oxidise to the corresponding disulfide 
under Boc protection conditions (Section 2.1). By conjugating the cysteine with 
tetrachloroethylene initially, the ability of the product to oxidise during the subsequent Boc 
protection is removed. However, the reaction proposed by Bartels and Miner (1990) proved 
troublesome in the current setting, due to formation of an inseparable impurity.  The 
synthetic methodology consisted of a reaction between L-cysteine and tetrachloroethylene 
Equivalent
Aqueous PhaseOrganic Phase
 
Figure 2.1. Species formed during the Boc protection of L-cysteine  
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in the presence of the base 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), with the desired TCVC 
rapidly crystallizing upon addition of acid61. Attempts to purify the product proved 
unsuccessful. The problem stems from the insolubility demonstrated by TCVC and the 
impurity in essentially all solvents tested. Solubility was observed only in DMSO, 100 °C 
water and aqueous base. This effectively ruled out column chromatography as a viable 
option. Both pH dependent, and hot water recrystalization failed to yield any improvement 
in purity. Hence attempts were made to remove the impurity altogether. The impurity 
obtained had a similar 1H NMR spectrum to the desired product and as such it was initially 
thought to be a disubstituted tetrachloroethylene.  
The attempts to minimise the formation of the impurity are outlined in Table 2.3. 
Performing the literature method described by Bartels and Miner (1990) resulted in a 2 : 1 
mixture of desired product to impurity. If the impurity present was the disubstituted 
tetrachloroethylene, it stands to reason, that by increasing the amount of 
tetrachloroethylene relative to cysteine the probability of disubstitution would be reduced. 
With this in mind, the equivalents of tetrachloroethylene were doubled to eighteen. This 
resulted in an improved ratio of TCVC to impurity (4 : 1). Following this promising result the 
equivalents of tetrachloroethylene were increased further to 24 and the cysteine added 
dropwise to further dilute the cysteine relative to tetrachloroethylene. Surprisingly these 
reaction conditions caused an increase in the amount of the impurity produced such that it 
represented the majority of product formed (TCVC : impurity, 3 : 7). Increasing the 
equivalents of tetrachloroethylene to 200 and adding dropwise resulted in a similar ratio 
(TCVC : impurity, 1 : 3). The reversal in the selectivity towards the impurity upon dropwise 
addition suggests that a disubstituted tetrachloroethylene is not the impurity and also 
indicates there may be additional factors, independent of dilution, governing selectivity. 
Apart from the dilution of cysteine (relative to tetrachloroethylene), the major change in 
regards to reaction conditions in the dropwise addition is the solvent system. Although both 
the dropwise and bulk addition reactions contained an overall equal quantity of DMSO 
relative to tetrachloroethylene, the variation occurs during the initial stage of the reaction. 
Upon addition of the first drop of cysteine in DMSO, the DMSO concentration is very low, 
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gradually rising in to reach its peak concentration upon addition of the last drop. At this 
point the DMSO concentration will be the same as the bulk addition reaction. This means 
the initial stages of the dropwise reaction will have a significantly lower polarity solvent 
system, which may be the cause of the observed changes in product ratios. Unable to 
remove or separate the impurity, the mixture was then subjected to Boc protection. 
Successful purification was achieved at this stage, albeit in a low 15% yield.  
The troubles with the inseparable impurity and a low yielding Boc protection prompted 
investigation into an alternative route for the formation of N-Boc-TCVC. This new route 
involved a reversal of the tetrachloroethylene conjugation and Boc protection steps, 
whereby the Boc-group is added prior to tetrachloroethylene conjugation. Using the 
previously synthesized Boc-Cysteine (Section 2.1), the synthesis of the desired N-Boc-TCVC 
was achieved through tetrachloroethylene conjugation, via an analogous method to that of 
Bartels and Miner (1990). Initial attempts involved using the same reaction conditions used 
previously for TCVC formation61. Although 1H NMR evidence indicated the reaction was 
successful, the desired product was unable to be efficiently isolated from the DMSO as, 
unlike TCVC, it could not be recrystallized. In an attempt to simplify the workup and allow 
for easier purification the reaction was trialled in dichloromethane. Unfortunately, the  
  
16
Impurity
DBN (2 eq), DMSO
Tetrachloroethene
 
Table 2.3. Reaction of L-Cysteine with Tetrachloroethylene 
 
Reaction Tetrachloroethylene (eq.) Dropwise Additiona TCVC : Impurityb 
1 9 No 2 : 1 
2 18 No 4 : 1 
3 24 Yes 3 : 7 
4 200 Yes 1 : 3 
aDropwise addition of L-cysteine hydrochloride in DMSO  and DBN. bDetermined by 1H NMR 
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reaction did not proceed in this solvent. The reason for the lack of reactivity was put down 
to the lower polarity of dichloromethane in comparison to DMSO and, as such, a reduced 
ability to stabilise the dipolar transition state. With this in mind the more polar acetonitrile 
was trialled, which gratifyingly gave the desired N-Boc-TCVC in 74% yield.  
The 1H NMR of this reaction showed two sets of peaks. These peaks were also seen in the 
spectrum of N-Boc-L-cysteine and were thought to be a result of rotamers caused by the 
steric bulk of the Boc group. To confirm this was the case, N-Boc-TCVC was subjected to 
treatment with 20% TFA in dichloromethane for 30 minutes, after which time, the solvent 
was evaporated off. Subsequent 1H NMR analysis revealed a single set of peaks, confirming 
the second set of peaks present in the 1H NMR spectrum of N-Boc-TCVC was due to the 
presence of rotamers (Figure 2.2).  
In summary, the successful synthesis of N-Boc-TCVC was achieved in two steps (46%), 
through the Boc-protection of L-cysteine and subsequent conjugation of 
tetrachloroethylene. Thus completing one of the initial objectives required to complete the 
main aim, i.e. the synthesis of mycothiol analogue 13.   
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Figure 2.2. 1H NMR spectrum comparing the α and β protons of Boc-TCVC and TCVC 
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Chapter 3   
3. Synthesis of α- and β-GlcN-Inositol 
Analogues  
Along with the synthesis of N-Boc-TCVC, another objective required to complete the 
synthesis of the mycothiol analogue 13 was the synthesis of the α-GlcN-inositol analogue 
10. This chapter outlines the successful synthesis of this fragment, while also introducing a 
new secondary aim, which involves the formation of the β-anomer of the original synthetic 
target 13. Thus, this chapter also features the successful synthesis of the β version of the 
α-GlcN-inositol analogue 10.   
 
3.1 Radical Based Synthesis to α-Thioglycoside (9)  
 
As stated previously (Section 1.6.1), there are two key challenges in GlcN-inositol synthesis. 
These are the formation of the 1,2-cis-α-linkage connecting the inositol to the glucosamine 
and the steroselective derivatization of the inositol ring52-54. Knapp et al. (2002) solved 
these problems by developing a GlcN-Inositol analogue in which the inositol hydroxyls were 
removed and the glycosidic oxygen linker was replaced by a sulfur18. Implementing these 
changes meant the stereoselective derivatization of inositol was redundant and the 
substitution of the linker oxygen with sulfur ment the 1,2-cis-α-linkage could be obtained 
selectively through a radical-based mechanism. These changes ultimately resulted in a 
significantly higher overall yield compared to previous mycothiol syntheses18. For these 
reasons the GlcN-inositol analogue developed by Knapp et al. (2002), as well as the 
synthetic steps used to make it, were chosen as the primary target. 
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3.1.1 Synthesis of β-D-Glucosamine pentaacetate 
 
The starting material used in Knapp's synthesis is β-D-glucosamine pentaacetate. It was 
envisioned this could be synthesized from N-acetylglucosamine in a peracetylation 
reaction62. A key challenge in this area is acetylation of six membered sugars so as to 
stereoselectivly obtain either the α or β anomer. In regards to glucosamine peracetylation 
there are simple stereoselective methodologies for the formation of the α-anomer, of 
which the most widely used is pyridine with acetic anhydride63-67. However, there is very 
little literature regarding high yielding β-glucosamine pentaacetate procedures to date. In 
fact, the most common routes to the synthesis of β-D-glucosamine pentaacetate require 
multistep processes68-72.  
Knapp et al. (2007) developed a method for the synthesis of β-glucosamine pentaacetate 
from N-acetyl glucosamine in a one step reaction utilizing montmorillonite K10 and acetic 
anhydride, albeit in a low yield (33%)62. Nonetheless, this reaction was chosen as a good 
starting point due to its simplicity and ability to be performed in a single step. 
Disappointingly, when the 2007 methodology of Knapp et al. was followed, a complex 
mixture of products was formed, as demonstrated by 1H NMR analysis of the crude reaction 
mixture. Present in this mix were the α and β anomers of glucosamine pentaacetate in  
a 50 : 50 ratio, relative to each other. Recrystallization of the mixture was attempted, 
though only 1% yield of the β-anomer was isolated. The reaction was repeated multiple 
times; in each case a complex mixture of products resulted. 
NaOAc, Ac2O
100 °C, 1 h
10%
5 6  
Scheme 3.1. Synthesis of β-D-glucosamine pentaacetate 
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In an attempt to produce a cleaner, higher yielding reaction, synthetic methodology used 
to produce β-D-glucose pentaacetate was trialled73.  The reaction involved heating the N-
acetyl glucosamine at 100 °C for 1 h in acetic anhydride and sodium acetate, producing both 
α- and β-glucosamine pentaacetate anomers in a ratio of 25 : 75 (β : α). The mixture was 
recrystallized from methanol to give a yield of 10% for the β-anomer (Scheme 3.1). Thus, 
although the ratio of the β-anomer relative to the α-anomer was lower, the overall yield 
was significantly higher than the montmorillonite K-10 procedure. This is due to the fact 
that production of the α and β glucosamine pentaacetates occurred in the absence of the 
complex mixture that was obtained from the Knapp methodology. 
 
3.1.2 Cyclohexane Conjugation 
 
3.1.2.1 Formation of Mercaptan (8) 
 
The synthesis of the thioglycoside 9, from β-D-glucosamine pentaacetate could be achieved 
through the methodology used by Knapp et al. (2002)18. This involved treatment of β-D-
glucosamine pentaacetate with Lawesson's reagent in toluene at 80 °C. This reaction 
proceeded to form thiazoline 7 in 68% yield62. The apparent difference in yield seen 
between Knapp's synthesis (100%) and the yield obtained may be due to the quality of the 
Lawesson's reagent. The Lawesson's reagent used was over 5 years old. The thiazoline 7, 
when treated with TFA and water yielded mercaptan 8 in quantitative yield (Scheme 3.2)74. 
The final step in the formation of thioglycoside 9 was the radical induced conjugation of 
cyclohexene to mercaptan 818. However, this step proved extremely problematic; as 
discussed below.   
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3.1.2.2 Radical Induced Thioglycoside Formation 
 
Knapp et al. (2002) reported the synthesis of thioglycoside 9 in 79% yield via a AIBN-induced 
radical reaction between mercaptan 8 and cyclohexene in chloroform (cyclohexene : 
chloroform 1 : 1 v/v) at reflux18. However, following this procedure none of the desired 
product was obtained. 1HNMR and IR spectroscopy of cyclohexene and AIBN, respectively, 
suggested that both regents were of good quality. Successful reactions using the same 
batch of AIBN, performed by various members of the research group also suggested that 
the AIBN was good in quality. Due to the high number of variables in this reaction (i.e. 
solvent, time, initiator, initiator equivalents, initiator addition sequence, cyclohexene 
addition sequence, and whether or not the reaction is performed in a nitrogen atmosphere) 
a series of experiments were performed to identify general trends in an attempt to improve 
on the yield (Table 3.1). 1HNMR evidence from the reactions performed in the presence of 
air showed small amounts of the disulfide 18 was produced (reactions 1). In contrast all 
AIBN reactions that were performed in the presence of nitrogen resulted in the recovery of 
a portion of starting material, suggesting the  
 
 
 
 
68 %
100%
6 7 8
Lawesson's Reagent
Toluene, N2, 2 hr, 80°C
TFA, MeOH, H2O
 
Scheme 3.2. Synthesis of mercaptan 8 
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oxidation may have been a result of atmospheric oxygen and not a radical based 
mechanism. THF proved to be the solvent of choice, as all AIBN reactions performed in THF 
saw an improvement in both yield and the amount of starting material recovered. Using a 
model reaction, both benzoyl peroxide and tertbutylperoxide were investigated as 
potential initiators for this reaction.  They were chosen over the hydroperoxides due to 
their lower propensity to cause oxidation. Furthermore, as they exhibit lower (tert-butyl 
peroxide) and higher (benzyl peroxide) decomposition rates relative to AIBN, these 
initiators enable analysis as to the effect that initiator decomposition has on the reaction75. 
In addition, as amines have been shown to increase the decomposition rate of benzoyl 
peroxide an extra reaction in which aniline was added to benzoyl peroxide was investigated 
8
Initiator, Cyclohexene
Solvent, reflux
9  
Table 3.1 Optimization of Radical Induced Thioglycoside Formation 
 
Reaction      Solvent  Time   Initiator   
Initiator 
eq.a  
Cyclohexene 
eq.b 
Nitrogen % Yield 
Recovered 
Starting 
Material 
Yield 
brsmc  
1 Chloroform 2 hr AIBN 0.65 x2 40 No - No   - 
2  Chloroform   2 hr AIBN      0.6 x 2  40    Yes  12  Yes  18 
3 THF    2 hr AIBN    0.7 x 3 40    Yes  17  Yes  35 
4 THF    5 hr AIBN  
   0.065 
x 2 
40    Yes  19 Yes   38 
5  THF    5 hr 
Benzoyl       
Peroxide 
   0.25 x 
5 
40    Yes  25 No   25 
6  THF    5 hr 
Benzoyl 
Peroxide 
  0.065 
x 2 
40    Yes  15 Yes   16 
7 
 1,4 
Dioxane  
  5 hr 
Benzoyl 
Peroxide 
  0.065 
x 2 
40    Yes  12 Yes   15 
8   THF    7 hr  AIBN   
  (0.02 x 
5) + (0.6 
x 2) 
8 x 5    Yes  29 Yes   48 
aThe first aliquot of initiator was added at start of reaction, each subsequent aliquot was added 1 h after the previous                           
aliquot, with the exception 3, where it was added in 40 min intervals. bFor reactions with multiple iterations,                                                              
the first aliquot of cyclohexene was added at start of reaction, each subsequent aliquot was added 1 h after the previous                           
aliquot. cYield based on recovered starting material.  
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to provide increased scope in regards to rate of decomposition75. Of the three sets of 
reaction conditions, employing benzoyl peroxide in the absence of aniline showed the most 
promise. However, when benzoyl peroxide was added in place of AIBN, in the thioglycoside 
formation reaction, there was little improvement in yield, as well as a reduction in 
recoverable starting material. The total equivalents of initiator appear to have little effect; 
rather a higher yield is favoured in reactions where multiple iterations of initiator are added 
over a longer period of time, as seen in reactions 6 and 9.  After canvassing a variety of 
reaction conditions the yield was ultimately raised from 0 to 29% (48% brsm). The highest 
yield was obtained using THF as a solvent and AIBN as the initiator, under a nitrogen 
atmosphere. It contained the highest number of AIBN additions over the longest period of 
time and added cyclohexene in five iterations. While this yield was a significant 
improvement it was still not ideal. As such alternative methods were sought to form the 
desired thioglycoside 9.  
 
 3.1.3 Attempt at SN2 Type Thioglycoside Formation 
 
A SN2-type reaction was examined in order to circumvent the low yields obtained in the 
radical induced thioglycosidation. The reaction design was inspired by a paper by Schmidt 
and Zhu (2004), which conjugated the same mercaptan 8 to peptides in which the primary 
hydroxyl of serine was derivatized to a bromine76. This peptide was then subjected to 
nucleophilic attack by the sulfur of 8 in a biphasic reaction consisting of aqueous sodium 
bicarbonate, ethyl acetate and the phase-transfer catalyst tetrabutylammonium hydrogen 
sulfate (TBAHS)76. However, when mercaptan 8 was exposed to these conditions, in the 
presence of bromocyclohexane, none of the desired thioglycoside 9 was observed. Instead 
there was complete conversion to the disulfide 17 (Scheme 3.1). The reason for this 
disparity is mostly likely due to the steric difference between the primary bromide in the 
amino acids and the secondary bromide in the bromocyclohexane. This difference is further 
exaggerated by the cyclohexane ring, in which axial hydrogens will block nucleophilic attack 
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of the sulfur (Scheme 3.3). With the SN2 mechanism proving futile and the radical based 
method not optimal, focus was shifted from synthesising the α-thioglycoside 9 to the 
corresponding β-thioglycoside 22.  
 
 
 
 
 
 
 
 
3.2 Synthesis of the β-tetraacetate thioglycoside (22) 
 
Although of no use in the synthesis of the desired compound 13, the formation of the β-
thioglycoside 22, was deemed advantageous for two reasons. Firstly, it can be used as a 
model substrate in the radical induced thioglycosidation and subsequent reactions. This 
would limit the unwanted loss, in future optimizations, of the small amount of the α-
thioglycoside 9 that had been previously obtained. Secondly, β-thioglycoside 22 provides 
the opportunity to synthesize the opposite anomer of the desired target 13, which would 
provide an interesting comparison in biological testing. It was envisioned that the formation 
of thioglycoside 22 could be obtained via a Lewis acid-catalyzed reaction between 
trichloroacetimidate 20 and cyclohexane thiol. 
 
8 17
EtOAc, NaHCO
3(aq)
TBAHS
 
 
Scheme 3.3. Attempted formation of thioglycoside 9 through SN2  type reaction 
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3.2.1 Trichloroacetimidate induced thioglycoside formation 
 
The use of trichloroacetimidates in glycoside synthesis was first demonstrated by Schmidt 
and Michel (1980)77. Since then they have found widespread use, owing to their ease of 
installation and ability to be activated without the presence of heavy metal salts; as is the 
case for many halo sugar electrophiles78, 79. With these advantages in mind, the 
trichloroacetimidate 20 was chosen as a potential glycosyl donor for the production of 
thioglycoside 22 (Scheme 3.4).  
The synthesis of trichloroacetimidate 20 has been reported in the literature65. Its formation 
involves the anomeric deacetylation of α-D-glucosamine pentaacetate and subsequent 
derivatization of the newly formed hemiacetal to the trichloroacetimidate65. Following 
these methods, anomeric deacetylation of α-D-glucosamine pentaacetate 18 was achieved 
using ethylene diamine and acetic acid in THF, proceeding smoothly to afford hemiacetal 
19 in 70% yield. Hemiacetal 19 was subsequently reacted with trichloroacetonitrile in the 
presence of DBU to afford 20 in 67% yield (Scheme 3.4). 
 The final step in the sequence, involved thioglycoside formation via BF3·OEt2 catalyzed 
conjugation of cyclohexanethiol to trichloroacetimidate 2080. When trichloroacetimidate 
20 was subjected to the BF3·OEt2 conditions outlined in literature, the β-D-thioglycoside 22 
represented the majority of product isolated (35%), followed closely by the oxazoline 21 
(30%), suggesting that the reaction proceeds through an oxonium ion formation (Scheme 
3.4).   
As an aside, the observation that it was possible to form the oxazoline under these BF3·OEt2 
catalyzed conditions prompted the testing of the thioamide equivalent of the 
trichloroacetimidate 20, under the same conditions (minus the cyclohexane thiol). This was 
looked into as a way to utilize the α-glucosamine pentaacetate 18 in the formation of 
thiazoline 7. Surprisingly, no thiazoline was detected under these conditions. Thus, this 
route was never examined further.  
41 
 
The trichloroacetimidate producedure outlined above did, however, succeed in producing 
the desired β-thioglycoside 22, albeit in a disappointing overall yield (17%), from α-
glucosamine pentaacetate. As stated above this anomer was of interest as it provides an 
interesting point of comparison in biological testing (see section 4.2). Hence, the β-anomer 
was developed alongside the α-anomer for the remainder of the synthesis.  However, the 
ability to use β-thioglycoside 22 as a model substrate, to prevent unnecessary loss of the α-
anomer, was hampered due to the poor yield obtained. Thus, a more direct approach was 
trialled. This involved the use of α-glucosamine pentaacetate as a glycosyl donor and 
cyclohexanethiol as the acceptor. 
 
  
70% 67%
22: 35%
21: 30%
Diaminoethane, THF
Acetic Acid, rt, 24 hr 
Cyclohexanethiol, BF
3
.OEt
2
Trichloroacetonitrile
CH
2
Cl
2
, -42 °C, 1 hr
22
DBU, 0°C, 2 hr
21
18 19 20
 
Scheme 3.4. Synthesis of β-Thioglycoside 22 via trichloroacetimidate 20 
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3.3 Direct Route to Thioglycoside Formation 
 
3.3.1 Reactivity of peracetylated sugars 
 
The formation of thioglycosides from peracetylated sugars is prevalent throughout 
literature, in most cases the reaction is Lewis acid mediated. The reason for their 
widespread use is, in part, a result of easy access to the acetate protected precursors81. 
However, although they are easily accessible, peracetylated glycosyl donors are known to 
be among the most unreactive, particularly in comparison to glycosyl donors with ether 
protecting groups, e.g. benzyl. Fraser-Reid termed this difference in reactivity the "armed-
disarmed theory"82. The theory states that glycosyl donors are significantly more reactive 
when protected with ether groups (armed), as opposed to esters (disarmed). The difference 
in reactivity is put down to the higher electron withdrawing effects of the ester protecting 
groups. As a result, this causes a decrease in stability of the oxonium ion intermediate. 
Consequently, there is an increase in the activation energy and a corresponding decrease 
in reactivity83. The decrease in reactivity is further exacerbated if the acetatylated sugar has 
a 1,2-α-cis configuration. The lack of reactivity demonstrated in 1,2-α-cis peractylated 
donors, in comparison to 1,2-β-trans peracetylated donors, is thought to be due to 
neighbouring group participation, whereby the C-2 acetate group aids in the departure of 
the anomeric leaving group in the 1,2-β-trans configuration; but is unable to do so in the 
case of the 1,2-α-cis configuration84.   
Li et al. (2011) examined the issue of poor reactivity seen when using 1,2-α-cis peractylated 
sugars as glycosyl donors in Lewis acid catalyzed thioglycosidation reactions. They showed 
that the reactivity of 1,2-α-cis peractylated sugars could be enhanced by increasing the 
reaction temperature85. Furthermore, the change in temperature was shown to be more 
important to activity than the strength of the Lewis acid used.  Most importantly, with 
respect to this thesis, it was found that by increasing the temperature from room 
temperature to 50 °C, the thioglycosidation reaction utilizing α-glucosamine pentaacetate 
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and thiophenol was able proceed, producing the β-thioglycoside in 40% yield85. 
Unfortunately, Li et al. (2011) did not report any α-thioglycoside under these conditions. 
Nonetheless, as stated previously, the β-anomer was still desired (3.2) and so a direct 
thioglycosidation based off of Li et al's (2011) work was attempted to try to improve on the 
16% overall yield obtained through the trichloroacetimidate route85. 
 
3.3.2 Synthesis of α- and β-Thioglycoside Directly from α-Glucosamine pentaacetate   
  
The synthesis of 22 was attempted using Li et al's (2011) methodology (Scheme 3.5)85. 
Surprisingly, when α-glucosamine pentaacetate 18 and cyclohexanethiol were exposed to 
these conditions, i.e. 2 eq. of BF3.OEt2 in dichloroethane at 50 °C, the desired α-
thioglycoside 9 was the major product formed, in 22% yield. The β-thioglycoside 22 was 
also formed in the reaction, being produced in 11% yield.  This fortuitous result was a 
contrast to the result obtained by Li et al. (2011), who obtained the β-anomer in 40%, albeit 
with thiophenol as the glycosyl acceptor85.  Interestingly, the major product formed in this 
reaction contains a 1,2-α-cis glycosidic linkage. These are one of the most difficult linkages 
to make and often require either derivatization of the anomeric leaving group to something 
that undergoes SN2-type displacement, such as iodine, or, alternatively, the use of 
unconventional protecting groups that take multiple steps to put in place86.  Furthermore, 
it produced the 1,2-α-cis glycosidic linkage in the presence of an acetamide protecting 
group that typically favours the formation of the 1,2-β-cis glycosidic linkage through 
neighbouring group participation87.  
Having produced a somewhat surprising, albeit advantageous result, a re-examination of 
the literature was performed in order to gain a better understanding of the mechanism that 
leads to the α-thioglycoside being formed preferentially. There is a considerable  
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amount of literature involving the Lewis acid catalysed glycosidation of peracetylated 
glucose or glucosamine. The vast majority of these reactions report the exclusive formation 
of the β-glycoside88-92. However, there are a number of studies that report the preferential 
formation of the α-glycosides through anomerization87, 93, 94.  
 
3.3.3 Anomerization Reaction Mechanism  
 
Anomerization is the conversion of one anomer to another over a period of time, in this 
case conversion of the β-thioglycoside to the α-thioglycoside. This process is reversible and 
as such will reach an equilibrium between the two anomers if enough time is given95. It is 
widely known that underivatized sugars, such as D-galactose and D-glucose, undergo 
anomerization in solution through a hemiacetal ring opening mechanism. In contrast, 
glycosides typically need a Lewis acid catalyst for anomerization to take place95. There are 
two possible mechanisms through which anomerization may take place in glycosides; these 
are through endocyclic or exocyclic bond breakage93. The exocyclic mechanism proceeds 
Cyclohexanethiol, BF
3
.OEt
2
1,2-Dichloroethane, 55 °C, 72 hr
18
22
9
 
Scheme 3.5. Synthesis of α- and β-thioglycosides 9 and 22 directly from peracetylated                               
glucosamine 
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via breaking of the glycosidic linkage, forming the oxonium ion. The newly formed oxonium 
ion intermediate can subsequently be attacked from either the top or bottom face, forming 
the β-anomer or α-anomer respectively. The endocyclic mechanism proceeds through 
cleavage of the bond between the ring oxygen and anomeric centre. Once broken, what 
was the glycosidic bond is free to rotate, such that either the β-anomer or  α-anomer can 
be formed depending on the conformation when the ring is reformed (Scheme 3.6)93. 
Evidence for both endo- and exo-anomerization can be found in literature. Xue et al. (2009) 
looked at tin tetrachloride and silver trifluoroacetate-catalyzed glycosidation reactions 
involving a range of alcohols87. They found that the smaller alcohols (methanol, ethanol and 
isopropanol) had the propensity to undergo anomerization to form their corresponding α-
anomers. They suggested that the mechanism itself goes through an exocyclization. This 
was based on the observation that the β-methyl glycoside, when subjected to Lewis acid 
catalysed glycosidation with isopropanol, resulted in the α-isopropyl glycoside as the major 
product87. Although this does not rule out the endocyclic anomerization, it does suggest 
that under these conditions anomerization occurs, at least in part, by exocyclic bond 
breakage. A paper by Pilgrim and Murphy (2010) looked at the tin and titanium 
tetrachloride catalyzed anomerization of O- and S-glycosides93. As they were able to trap 
and isolate a ring opened intermediate, formed as a consequence of endocyclic ring 
opening, the study suggested that endocyclic anomerization was the cause of the observed 
anomerization93. However, once again this does not prove there is no anomerization taking 
place through exocyclization, only that some endocyclic anomerization is taking place. 
Regardless of which mechanism is taking place, or whether a combination of the two is 
occurring, these studies demonstrate that anomerization of peracetylated sugars can 
occur. Furthermore, this anomerization can result in the preferential formation of the α-
anomer.  
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The study performed by Pilgrim and Murphy (2010) also provided additional information 
which pointed to anomerization as a likely cause of the selectivity.  The study tested a large 
selection of variables in regards to anomerization, a number of which were of particular 
interest. It was noted that S-glycosides had a higher propensity to undergo anomerization, 
compared to their corresponding O-glycosides, although selectivity towards the α-glycoside 
was significantly lower93. Additionally, it was found that higher temperatures resulted in a 
increase in the rate of anomerization and decrease in α-glycoside selectivity. In contrast a 
higher catalyst loading resulted in a increase in α-glycoside, relative to the β-glycoside. All 
things considered, the reaction described in this thesis, involving the formation of α-
thioglycoside 9 from the peracetylated-α-D-glucosamine, fits nicely with the observations 
made by Pilgrim and Murphy (2010)93. Although a slightly different starting material, Lewis 
acid and solvent were used, based on Pilgrim and Murphy's (2010) observations, 
anomerization would be expected to take place because high temperatures, high catalyst 
loading and the formation of thioglycosides, all favour anomerization. Furthermore, the α : 
β ratio of 2 : 1 also aligns closely to what was observed by Pilgrim and Murphy (2010)93. 
Exo-Cyclic Anomerization 
 
Endo-Cyclic Anomerization 
 
Scheme 3.6. Possible anomerization mechanisms.                                                                                                      
LA = Lewis Acid. Adapted from Pilgrim 
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TLCs taken over the course of the reaction also supported anomerization as a likely 
mechanism. The TLCs showed an initial build up of the β-anomer. This was followed by an 
increase in the α-thioglycoside, relative to the β-thioglycoside, as the reaction progressed. 
All things considered, it is interesting that Li et al. (2011) made no mention of any α-
thioglycoside formation when using the same conditions described in this thesis, with the 
only variable being the use of thiophenol in place of cyclohexane thiol85. 
 The contrasting results seen when using cyclohexanethiol instead of thiophenol, may be 
due to a number of factors. Firstly, Li et al. (2011) may have obtained, but not reported the 
α-thioglycoside. This seems unlikely, given the paper was demonstrating how to improve 
the reactivity of 1,2-cis-α-peracetylated sugars, and not out to synthesise the β-
thioglycoside specifically. Alternatively, it is plausible that the β-phenylglycoside may be 
more stable than the corresponding α-phenylglycoside, greatly favouring the formation of 
the β-phenylglycoside, and resulting in none of the α-phenylglycoside being observed. 
Finally, it is possible that the observed difference in reaction outcomes is down to the S-
phenyl glycoside having a significantly greater energy barrier to anomerization to 
overcome, relative to the S-cyclohexyl glycoside. Irrespective of how they are occurring, the 
differing results seen between the experiment performed in this thesis and the one 
performed by Li et al. (2011) were highly advantageous. 
Due to time constraints additional experiments were not able to be performed. However, 
to confirm anomerization is taking place, the β-thioglycoside 22 could be subjected to the 
same reaction conditions (α-glucosamine pentaacetate excluded) used in the thioglycoside 
forming reactions. This would ascertain whether 22 is in fact getting converted to the α-
thioglycoside 9, as the TLC suggests, or whether it is getting formed in parallel. Secondly, 
the reaction could be optimized to improve on the modest yield of 33% (2 : 1, α : β). As 
BF3·OEt2 has been implicated as the main cause of product degradation in a number of 
studies, its replacement would be a good starting point for optimization85, 87.  Pilgrim and 
Murphy (2010) found SnCl4 as the best Lewis acid for promoting anomerization in 
peracetylated glucose thioglycosides, so it would represent a good starting point93. Even 
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without optimization the reaction provided a very practical means of synthesizing both the 
α and β anomers and possessed many advantages over the syntheses of both the α-
thioglycoside 9 and β-thioglycoside 22 described previously. 
 
3.3.4 Comparison to Knapp's Methodology 
 
There are a number of inherent advantages to utilizing the direct route to thioglycoside 
formation in place of Knapp's (2002) synthetic route18. These advantages include: 1) The 
reaction can be performed on a large scale, producing gram scale quantities of both the α 
and β thioglycosides; 2) It utilizes the significantly more available α-glucosamine 
pentaacetate; 3) The desired thioglycosides can be synthesized from the α-glucosamine 
pentaacetate in just a single step, as opposed to the 3 steps for the synthetic routes used 
to synthesise α-thioglycoside 9 and β-thioglycoside 22 previously; 4) The overall yield 
(starting from N-acetyl glucosamine) for the formation of  α-thioglycoside 9  is higher than 
what was obtained using Knapp's route (12% vs 1.5%). However, the overall yield of the β- 
thioglycoside 22 was slightly less than the trichloroacetimidate route (6% vs 9%). In 
conclusion, this reaction, though currently only producing modest yields, upon 
optimization, may represent an effective way to synthesize the 1,2-α-cis-thioglycoside 9 
directly from easily accessed peracetylated sugars. Having successfully produced a large 
quantity of both the α-thioglycoside 9 and the β-thioglycoside 22, all that remained in the 
synthesis of the GlcN-inositol analogues was to deprotect the alcohols and amine by 
removing the acetates.       
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3.4 Acetate and Acetamide Deprotection 
 
The acetate and acetamide deprotection was originally proposed to be achieved through 
methodology used by Knapp et al. (2002)18. However, this reaction required the use of the 
highly toxic hydrazine at elevated temperatures over an extended period of time. 
Furthermore, purification required the use of a specific silca gel, namely Iatrobead silica18. 
With these limitations in mind, an alternative approach to acetate/acetamide deprotection 
was employed, which involves activating the acetamide, through addition of a Boc group, 
to allow for a more facile deprotection96.  
 
3.4.1 Addition of the Boc Group to Acetate Protected Thioglycosides (9) and (22) 
 
Activation of thioglycosides 9 and 22 was achieved by reacting them with di-tert-butyl 
dicarbonate in the presence of DMAP. The reaction was carried out in THF at 60 °C, 
producing N-Boc-α-thioglycoside 23 and N-Boc-β-thioglycoside 24 in 100% and 80% yield 
respectively (Scheme 3.7)96. Interestingly, the 1H NMR spectrum of the N-Boc-β-
thioglycoside 24 showed an approximately 1 : 1 ratio of two rotamers, which demonstrated 
different shifts for all protons, with the exception of the cyclohexane ring. In contrast the 
N-Boc-α-thioglycoside 23 showed just a single set of peaks. (Figure 3.1). 
 
α = 9
β = 22
α = 23 (100%)
β = 24 (80%)
DMAP, Boc2O, THF
reflux, overnight
 
Scheme 3.7. Boc activation of N-acetyl thioglycosides 9 and 22 
50 
 
Figure 3.1. 1H NMR of the α-Boc 23 and β-Boc 24 
51 
 
Interested in the apparent disparity between the two anomers, the structures were 
subjected to molecular modelling analysis utilizing MacroModel, which allowed 
examination of the lowest energy conformations for each anomer. The results showed that 
both the α and β anomer had two main populations of conformers; these, broadly, had Boc-
up or Boc-down features (Figure 3.2). In the N-Boc-β-thioglycoside, both these 
conformations were essentially the same in regards to their energy. In contrast, there was 
a difference of approximately 10 kJ mol-1 in the Boc-up and Boc-down versions of the N-
Boc-α-thioglycoside.  Alongside the lowest energy conformations, the other pertinent point 
to consider, in regards to the origins of the rotamers in the β-anomer, is the barrier to 
rotation between the Boc-up and Boc-down rotamers. An approximate value for this barrier 
was determined by rotating about the C2-N bond 360 degrees in 5 degree iterations for 
both the α and β anomers. It was found that in both cases the lowest energy pathway the 
rotation could proceed through had a near identical, and equally significant, energy barrier 
of approximately 70 kJ mol-1. This large value suggests that at room temperature both the 
α and β anomers will be unable to easily switch between conformations, and as such, the 
reason rotamers are observed in the β-anomer and absent in the α-anomer is likely 
determined during the course of the reaction. Initially it was thought that, given the high 
barrier to rotation, the rotamers present in the β-anomer may just be a representation of 
the conformation the acetamide was in when the nucleophilic attack took place. However, 
given the α-anomer had an equally high energy barrier to rotation and no rotamers were 
observed, this option seems unlikely. Furthermore, at the elevated temperatures under 
which the reaction was performed (60 °C), there is most likely enough energy in the system 
to overcome the 70 kJ mol-1 barrier to rotation and allow for interconversion between the 
conformers. Thus, it is more likely that production of rotamers in the β-anomer, and not 
the α-anomer, is due to the difference in energies between the Boc-up and Boc-down 
conformers of these anomers, i.e. a thermodynamic not a kinetic effect. As stated above 
there is very little difference between the Boc-up and Boc-down conformation in the N-
Boc-β-thioglycoside, whereas, the N-Boc-α-thioglycoside has a 10 kJ mol-1 difference 
between the two. This difference is  
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most likely negligible under the 60 °C reaction conditions; however, once the reaction 
mixture begins to cool down this difference in energy preferentially favours the lower 
energy conformer, resulting in the formation of this conformer in isolation. On the other 
hand, in the β-anomer there is only a small difference in energy between the two 
conformations, as such, a 50 : 50 mix of each conformer would be expected, such as is seen 
experimentally. Thus, both the experimental observations and molecular modelling suggest 
that the reason for the disparity between the α and β anomers, in regards to rotamers, is 
due to, firstly, to a high rotational barrier for both anomers, and secondly, the presence of 
a significant energy difference in the conformations of the α-anomer that is not present in 
the β-anomer.   
β-Boc-up β-Boc-down 
 
 
α-Boc-up α-Boc-down 
 
 
Figure 3.2. Molecular models of the lowest energy Boc-up and Boc-down conformations for the 
α-Boc 23 and β-Boc 24.  
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Putting the difference in rotamers aside, the purpose of the placing the Boc group on was 
to allow for a more facile deprotection of the acetamide. Thus, with it in place, attempts 
were made to remove all the acetate groups, the acetamide and newly added Boc group in 
a sequential one-pot deprotection.   
 
3.4.2 Deprotection of Boc, Acetamide and Acetate Protecting Groups from (23) and (24) 
 
With the Boc group in place, both the O-acetates and the N-acetate could be removed 
under relatively mild conditions, using sodium methoxide in methanol at room 
temperature. Concentration of the reaction mixture, followed by addition of concentrated 
aqueous hydrochloric acid formed the desired deprotected sugars 25 and 26 as 
hydrochloride salts96. Hence, the removal of the acetates/acetamide and Boc protecting 
groups, was performed in a one-pot reaction and the only work up that was required was 
the removal of the solvent in vacuo (Scheme 3.8). This meant there was no loss of material 
during the deprotection steps. However, this did mean sodium chloride remained mixed in 
with the desired products. With access to both the GlcN-inositol analogues 25/26 and the 
cysteine derivative 3, all that was required was to conjugate both fragments together. The 
presence of sodium chloride was deemed not to be a problem in regards to the following 
conjugation step. Thus no attempt was made to remove it. 
α = 23
β = 24
α = 25
β = 26
i) Na0, methanol, rt, 1 hr
ii) HCl(aq), methanol, rt, 12 hr
 
Scheme 3.8. One-pot deprotection of N-Boc thioglycosides 23 and 24 
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Chapter 4 
4. Synthesis of Mycothiol Analogues and 
Biological Studies  
 
This chapter outlines the successful synthesis of the original synthetic target, mycothiol 
analogue 13. As well as the structurally related β-anomer 28. Thus completing the main 
aim of this thesis. These compounds, along with two of their precursors, were submitted 
for testing against Mycobacterium smegmatis, Mycobacterium boivs (BCG strain) and 
HL60 cells, the results of which are also discussed.  
 
4.1 Coupling of N-Boc-TCVC and GlcN-Inositol Analogues  
 
The coupling of N-Boc-TCVC to the GlcN-inositol analogues 25 and 26 was modified from 
the literature procedure by Knapp et al. (2002)18. Differences included use of N-Boc-TCVC 
in place of the N-Boc-S-acetyl cysteine, as well as the use of amine hydrochloride salts for 
the GlcN-Inositol analogues. In Knapp's (2002) procedure N-Boc-S-acetyl cysteine and  the 
GlcN-inositol analogue 25 (as the free amine) were coupled in DMF using EDCI, affording 
an 82% yield18. These same reaction conditions were trialled, albeit with triethylamine 
added to neutralize the hydrochloride salt, in an attempt to produce the desired N-Boc-
mycothiol analogue 11 (Scheme 4.1). However under these conditions only a trace amount 
of product was obtained. TLC analysis throughout the reaction suggested that a significant 
amount of the starting material 25 was not reacting. With these observations in mind, an 
additional two equivalents of triethylamine were used in the next reaction, bringing the 
total number of equivalents to five. It was thought that this would be sufficient to 
deprotonate the carboxylic acids from the two equivalents of  N-Boc-TCVC, the 
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hydrochloride salt from the two equivalents of EDCI and the hydrochloride salt from 25. 
However, after 1 hr, TLC analysis suggested a large amount of starting material was still 
present; this prompted a further equivalent of a stronger base, DMAP, to be added in an 
attempt to progress the reaction. However, once again only trace amounts of the desired 
product was obtained. These results suggested that the sugar hydrochloride 25 was not 
being effectively deprotonated and as a consequence, leading to a reduction in its 
reactivity. In an effort to try and explore the ability of triethylamine to deprotonate 25, a 
large excess was used to quench the reaction in the Boc-deprotection step (section 3.4.2). 
This was expected to remove the remaining excess HCl and depronate 25. Surprisingly, 
none of the desired free amine of 25 was produced, instead, triethylamine hydrochloride 
and the protonated GlcN-inositol analogue 25 were the only compounds observed through 
1H NMR spectroscopy. This result added further weight to the hypothesis that the low 
yielding reactions were primarily resulting from the inability of triethylamine to 
deprotonate the hydrochloride salt of 25. Due to its low nucleophilicity and higher basicity, 
potassium tert-butoxide was chosen as a suitable replacement to triethylamine in the 
coupling reaction. A change in the addition of 25 was also employed, whereby, 25 and one 
equivalent of potassium tert-butoxide were stirred for 30 minutes in DMF, then 
subsequently added to a mixture of N-Boc-TCVC and EDCI. This change in base and reaction 
conditions resulted in the complete consumption of 25 (determined via TLC analysis). Using 
this method, the desired N-Boc-mycothiol analogues 11 and 27 were synthesized in 26% 
and 35% yield respectively (Scheme 4.1) (Note: due the presence of sodium chloride in the 
starting materials 25 and 26, these yields are calculated from the Boc-protected sugars 23 
and 24, see chapter 6 for details).   A likely cause of this low yield, despite the consumption 
of all the starting material, may be due to difficulties in purification. Initial attempts 
involved the use of flash chromatography on silica, as was used by Knapp et al. (2002)18. 
However, this resulted in substantial loss of product with each pass through the column, 
suggesting the product may have an undesirable interaction with the silica gel.  In an effort 
to avoid the product spending a lengthy time on the column, a series of quick elutions were 
performed on a short column of silica.  This involved, in order, use of:  petroleum ether; 
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dichloromethane; diethyl ether; ethyl acetate; and dichloromethane : methanol (3 : 2) as 
the eluents. Using this elution system the product was, for the most part, confined to the 
diethyl ether fraction, with small amount present in the ethyl acetate fraction. Subsequent 
1H NMR analysis of these fractions revealed the major impurity to be the excess N-Boc-
TCVC, which could be separated by trituration with chloroform. Although this method 
represented a vast improvement, there is still a lot of room for optimization, with trialling 
additional coupling agents being the next logical step.  
 
 
 
 
 
 
 
Two papers in the literature have used hydrochloride salts of GlcN-inositol analogues for 
coupling of cysteine derivatives, in both cases HATU was used as the coupling agent13, 53. 
With these studies in mind HATU would be a good choice for further optimization. Time 
pressures meant this option was never tested.  
With sufficient quantities of both the α and β anomers, all that remained in the synthesis 
of the desired mycothiol analogue was removal of the Boc protecting group. To achieve this 
α-Boc 11 was treated with neat TFA for 15 minutes and concentrated in vacuo. However, 
the subsequent 1H NMR revealed a significant amount of impurities, most of which were 
concentrated around 0 ppm. Given the quantity and positioning of the impurity in the 1H 
NMR, it was believed that these peaks were a product of degradation of the rubber, present 
in the vial adapter used to remove the TFA. Fortunately the impurities present were able to 
α = 13 (35%)
β = 28 (100%)α = 25
β = 26
N-Boc-TCVC, EDCI
Base, rt, 2 hr
TFA
α = 11 (26%)
β = 27 (35%)
  
Scheme 4.1. Formation of mycothiol analogues through N-Boc-TCVC conjugation and Boc 
deprotection 
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be removed via chloroform trituration, though as a consequence the yield obtained for this 
step was only 35 %. With only limited time and a small quantity of the starting material 11 
(which was set aside for biological testing), the reaction was never repeated in order to 
confirm the origin of the impurity. However, when the β-Boc 27, was tested under the same 
reaction conditions and concentrated in vacuo (this time without using a vial adapter) the 
TFA salt 28 was formed in quantitative yield. A subsequent CDCl3/TFA 1H NMR spectrum 
showed no signs of the impurity, although the peaks pertaining to the glucosamine protons 
showed extreme broadening. Unfortunately, by time a 1H NMR was performed in CD3OD, 
the compound showed signs of degradation (see appendix). Compound 28 will be re-
synthesized in the future to obtain full characterization data for publication. In regards to 
biological testing the issue with the degradation of 28 was deemed not to be a problem, as 
in each case the sample was prepared on the day of, or the day before, testing. In contrast, 
the alpha anomer 27 has exhibited no signs of degradation over storage in CD3OD for 2 
weeks.   
With the successful synthesis of the mycothiol analogues 13 and 28 the main aim of this 
thesis was complete. The optimized scheme leading to the synthesis of these products can 
be seen in scheme 4.2. Following their synthesis, the compounds were able to be tested for 
their biological activity.      
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Pyridine, Ac2O
rt, 18 h, 56%
22%11%
35%
26%
35%100%
22
18
Cyclohexanethiol, BF3.OEt2
TFA, rt, 20 min
iii) N-Boc-TCVC, EDCI,
     tBuOK, rt, 2 h
iii) N-Boc-TCVC, EDCI,
     tBuOK, rt, 2 h
9
i) Na0, methanol, rt, 1 h
DMAP, Boc2O, THF
i) Na0, methanol, rt, 1 h
ii) HCl(aq), methanol, rt, 12 h
DMAP, Boc2O, THF
ii) HCl(aq), methanol, rt, 12 h
reflux, 18 h
TFA, rt, 20 min
reflux, 18 h
1,2-Dichloroethane, 55 °C, 72 h
23
24
27
28
11
13
80% 100%
 
Scheme 4.2. Synthesis of mycothiol analogues 11, 27, 13, and 28 
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4.2 Biological Testing 
 
The original hypothesis stated that the synthesized mycothiol analogue 13, will be able to 
cause cell death in Mycobacterium tuberculosis, through an accumulation of harmful 
halothioketenes. It was theorized that this could occur through metabolism by Mca, or 
MshB, to form trichlorovinyl cysteine, which has the ability to undergo cleavage by β-lyases 
to release the halothioketene, hopefully resulting in cell death (section 1.4.2). 
Mycobacterium smegmatis  and BCG were both chosen to test this hypothesis. These 
mycobacteria both have the advantage of being non virulent, and as they both express 
Mca/MshB they should also produce halothioketenes on exposure to 13, making them ideal 
for initial investigations. The reason two mycobacterial assays were chosen is due to the 
variance in dependence on the mycothiol pathway exhibited by many mycobacteria. For 
example, while Mycobacterium tuberculosis is known to require the mycothiol pathway to 
be viable, while Mycobacterium smegmatis can survive even if the mycothiol pathway is 
completely absent. Furthermore, Mycobacterium smegmatis, being a soil bacterium, has 
many mechanisms in place to manage oxidative stress. Since halothioketene exposure, at 
least in part mediates its toxicity through oxidative stress, Mycobacterium smegmatis may 
be better suited to cope with the synthesized drug21. Thus, by testing against two strains 
the chance of drawing false conclusions, in regards to potential Mycobacterium tuberculosis 
activity,  is lessened.  An HL60 assay was also performed to give an indication of the 
selectivity of these compounds towards mycobacteria, hence, giving a crude indication of 
potential toxicity that may be observed in a clinical setting.  
Four compounds were chosen to have their activity against Mycobacterium smegmatis,  the 
BCG strain of Mycobacterium Bovis and HL60 cells tested. The α-TFA salt 13 was the original 
synthetic target of this thesis. The β-TFA salt 28 was synthesized as it makes, from a 
biological point of view, an interesting comparison and should in theory act as a negative 
biological control. Boc-protected precursors 11 and 27 were also tested as the increased 
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lipophilicty of the Boc-group may aid in cell entry, with the possibility of Boc removal 
occurring once inside the cell.  
The four synthesized compounds described above were all tested in Mycobacterium 
smegmatis by Nathanial Dasyam (from the natural products group at Victoria University of 
Wellington (VUW)). A green fluorescent protein (GFP) reporter and optical density (OD) 
were used to determine cell numbers and a resazurin reduction assay was used to 
determine the presence of metabolically active cells. The BCG assay was performed by 
Hilary Corkran (from the immunoglycomics research group at Malaghan Institute of Medical 
Research), using a resazurin-based detection. Activity against HL60 cells was assessed with 
assistance from Jessica Field (from the Centre for Biodiscovery at VUW), using an MTT 
assay. The results of these assays are shown in Table 4.1. 
 
 
 
 
 
 
 
 
The results obtained demonstrated a few interesting points. The most important results in 
regards to the hypothesis were those pertaining to compound 13. Gratifyingly, this 
compound proved to have the highest MIC against both types of Mycobacterium tested, 
the most promising of which was the MIC of close to 62.5 µM observed in BCG. Although 
not overly potent, this level of activity represents a good starting point for future 
development. Compound 13 also demonstrated the highest selectivity index (defined as 
Table 4.1. Activity of Synthesized Compounds Against Varying Cell Lines   
 
Compound Smegmatis  (MIC) BCG (MIC)  HL60 (IC50) 
Selectivity 
Indexb 
11  > 1000 µMa 500-1000 µM 59.6 ± 9.5 µM 0.12 - 0.24 
27 > 1000 µM  1000 µM 16.5 ± 0.2 µM > 0.017 
13 250 - 500 µM 62.5-125 µM 75.7 ± 1.4µM 1.2 - 0.6 
28 250 - 500 µM 125 -250 µM 112 ± 18.2 µM 0.9 - 0.45 
aOD and GFP suggest there was activity (IC50 = 4 µM); however, the maximum inhibition never drops below 30% of the                 
maximal growth. bSelectivity is defined as the MIC of BCG assay divided by the IC50 of the HL60 assay.    
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the IC50 of the HL60 cells divided by the MIC of BCG), at 0.6 to 1.2. However, this level of 
selectivity is lower than what would be deemed optimal, and may be indicative of potential 
for toxicity in a clinical setting. Nevertheless, it is worth pointing out again that the toxicity 
in HL60 cells is a very crude comparison and results against non-malignant cells and whole 
organisms may vary significantly. Regardless of its selectivity, the activity of compound 13 
towards BCG suggests cell penetrance is not an issue. At the beginning of this thesis the 
high polarity of the original synthetic target 13 was identified as a potential problem in 
regards to cell penetrance. This was part of the motivation behind the proposed synthesis 
of the fluorescent compound 14 as an objective, as well as the testing of the Boc 
compounds 11 and 27. However, although it appears the drug is getting into the cell, the 
mechanism through which it is entering unclear. It is possible that 13 is getting is getting 
into the cell through an active transport mechanism, as is known to occur with mycothiol97. 
Regardless, as a result of the activity seen, the synthesis of fluorescent compound 14 to test 
cell entrance was no longer required.    
Looking at compound 13 in isolation shows some promising results. However, when it is 
examined in context with the other three compounds some additional points of interest 
can be seen; particularly when compared to the compound that was originally designed to 
act as a negative control, i.e. 28. Surprisingly, this compound showed a similar level of 
activity to 13 in both the BCG and Mycobacterium smegmatis assays. This was unexpected, 
as it was hypothesized the change in stereochemistry at the anomeric centre would result 
in a significant conformational change, such that the compound would no longer be a 
substrate for Mca or MshB. Thus, the fact that activity is seen may indicate the 
streochemistry of the cyclohexane ring attachment only plays a very small role in 
recognition either by Mca or MshB. Alternatively, the toxicity observed may be 
independent of Mca/Msh B activity. With this in mind, one possibility is that the toxicity of 
these compounds is due to β-lysis of the compounds in their entirety. The mode of action 
will be tested in further studies.  
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Comparing the Mycobacterium smegmatis and BCG assays shows that, in general, 
compounds show a higher level of activity in BCG. This suggests that, as stated above, the 
ability of Mycobacterium smegmatis to cope with oxidative stress may be contributing the 
lower level of activity seen, in comparison to BCG21. The other interesting result seen in the 
smegmatis assay was the activity of the α-Boc 11, which showed contrasting results 
between the resazurin and GFP/OD detection methods. The resazurin results suggested 
100% growth (relative to control) was occurring up to the 1 mM concentration tested. In 
contrast, the OD and GFP detection methods both gave near identical IC50 values of 4.6 µM 
and 4.2 µM respectively. However, the OD and GFP data showed inhibition never dropped 
below 30% of maximal growth (relative to control). The reason for the apparent disparity 
may be due to the different ways each detection method determines cell growth. GFP and 
OD directly determine cell numbers through fluorescence and light scattering respectively, 
in comparison resazurin measures metabolic activity (through reduction of resazurin)98. 
One explanation of this effect is that 11 is bacteriostatic, leading to a reduction in cell 
numbers compared to the control, but retaining sufficient metabolic activity to reduce all 
the resazurin present. This could arise, for example, if α-Boc 11 is inhibiting one or more of 
mycothiol's biosynthetic enzymes. As stated above Mycobacterium smegmatis does not 
require mycothiol to survive, however, if its ability to produce mycothiol is inhibited there 
is a concurrent reduction in the growth rate21. However, given the low level of activity 
exhibited by 11 in the BCG assay this theory seem unlikely and further testing will be 
required to determine the cause of the activity. 
Finally, aside from providing a comparison to the mycobacterial assays, the HL60 assay had 
some interesting results of its own, particularly in regards to compound 27, which showed 
the highest level of activity, with an IC50 of 17 µM. Though the level of activity seen in 27  is 
well below what is seen in many natural products99, 100, it may hold promise as a lead 
compound for future investigations; particularly given it's unique structural features. 
In summary, the results obtained from the biological assays were satisfactory in terms of 
activity, with the original synthetic target 13 proving to have the highest MIC in both BCG 
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and Mycobacterium smegmatis assays. Surprisingly, it corresponding β-anomer 28 showed 
similar activity. These results suggest further investigations into the mechanism of toxicity 
and optimization of the activity, through structural changes, may be warranted.  
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Chapter 5 
5. Conclusions and Future Work 
 
5.1 Concluding Remarks 
 
The original goal of this thesis was to explore whether the mycothiol and β-lyase pathways 
present in Mycobacterium tuberculosis could be exploited in order to produce an 
accumulation of harmful halothioketenes, ultimately resulting in cell death. This 
combination provides a novel target and mechanism towards the treatment of 
tuberculosis. The original synthetic target 13 was a derivatized version of a simplified 
mycothiol analogue developed by Knapp et al. (2002)18. However, their synthetic route 
proved to be extremely problematic in our hands. Gratifyingly,  these problems were 
completely circumvented through a direct thioglycosidation of α-glucosmaine 
pentaacetate to form the α-thioglycoside 9 in 22% yield, accompanied by formation of the 
β-thioglycoside 22, which had previously been identified as a desired control compound, in 
11% yield. To avoid the use of hydrazine, the synthetic route to the deprotection of the 
thioglycosides 9 and 22 also involved deviation away from Knapp et al's (2002) synthesis. 
This was achieved by first activating the acetimide through addition of a Boc group, after 
which, a more facile deprotection involving Na0 in methanol followed by HCl was possible. 
The deprotected sugars 25/26 were coupled to TCVC, resulting in 11 and 27 in 26% and 35% 
yield respectively. The final step in the synthesis involved the treatment of 11 and 27 with 
TFA to afford the original synthetic target in 35% yield, while the corresponding β-anomer 
was produced in 100% yield. The N-Boc-TCVC used in the formation of 11 and 27 was 
synthesized in 46 % yield over two steps from L-cysteine. Whist some steps remain to be 
optimized, compounds 11 and 27 were produced in 3.2% and 1.7% yields respectively, over 
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4 steps (longest linear sequence). While, 13 and 28 were synthesized in 1.1% and 1.7% 
yields respectively, over 5 steps (longest linear sequence).   
Having successfully synthesized all the desired compounds, they were tested for their 
activity against Mycobacterium smegmatis, the BCG strain of Mycobacterium bovis and 
HL60 cells. The results obtained from these biological assays were satisfactory in terms of 
activity, with the original synthetic target 13 proving to have the MIC's of 250 - 500 µM and 
62.5 - 125 µM in Mycobacterium smegmatis and BCG assays respectively. Surprisingly, the 
corresponding β-anomer 28 showed similar activity. These results suggest further 
investigations into the mechanism of toxicity and optimization of the activity, through 
structural changes, may be warranted. 
 
5.2 Future Directives 
 
This thesis describes the synthesis a mycothiol analogue 13 and three other structurally 
related variants (11, 27 and 28). These were made to test whether mycothiol and β-Lyase 
metabolism could be selectively targeted in Mycobacterium tuberculosis, in order to 
produce an accumulation of harmful halothioketenes, with the end goal being cell death. 
Both interesting chemical and biological results were obtained on the way to achieving this 
goal that warrant future investigation. 
From a chemical perspective, the most interesting result obtained was the synthesis of the 
α-thioglycoside 9 directly from α-glucosmaine pentaacetate. If the reaction was able to be 
optimized further to improve on the 33 % yield (α : β, 2 : 1) obtained, it would provide a 
very easy access to Knapp et al's (2002) analogue, along with the added advantage of 
producing the β-anomer concurrently. In regards to yield the only other reaction that 
warrants further optimization is the coupling of the deprotected thioglycoside salts 25 and 
26 to N-Boc-TCVC. 
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From a biological perspective there are a number of interesting results that warrant further 
investigation. Firstly, the β-Boc compound 27 had an IC50 of 17 µM in the HL60 MTT assay. 
This level of activity is sufficient to suggest it may be worthwhile examining the use of this 
compound as a lead for the development of related compounds that may further enhance 
the anti-cancer properties.   
In regards to the Mycobacterium smegmatis assay, the activity of N-Boc-α-thioglycoside 11 
was promising (IC50 = 4 µM), despite its inability to cause complete cell death even at the 
highest concentration tested (1 mM). These results suggested 11 may be exerting a 
bacteriostatic effect. As such, it would be interesting to ascertain whether this is the case, 
as well as determining if prolonged exposure leads to a bacteriocidal effect. 
With respect to the original aim of this thesis, there are two main questions that remain 
unanswered. Firstly, although compound 13 (MIC 62.5-125 µM) and, to a lesser extent 28 
(125-250 µM), show activity, the mechanism through which this activity occurs is unknown. 
Thus, testing should be performed to elucidate the mechanism that leads to toxicity. 
Secondly, a structure activity relationship could be explored in order to evaluate whether 
to antimicrobial activity could be enhanced and the toxicity to human cells reduced. Given 
the methodology developed, a library of compounds could be easily synthesized by 
substituting the cyclohexanethiol used in the glycosidation step with a range of other thiols, 
in combination with, switching of the substituent conjugated to the sulfur of cysteine.     
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Chapter 6 
6. Experimental 
6.1 General Experimental  
 
Unless otherwise stated, the following conditions apply. All reactions were performed 
with magnetic stirring. Moisture- and oxygen sensitive liquids and solutions were 
transferred using a stainless steel syringe. Before use, solvents were refluxed over the 
appropriate drying agent and distilled under nitrogen; acetonitrile (MeCN) and 
triethylamine (NEt3) from calcium hydride; methanol (MeOH) and toluene from sodium. 
Dichloromethane, toluene and THF were used directly from Innovative Technology Pure 
Solv MD-5 solvent purifier.  Anhydrous N,N-dimethylformamide (DMF) and acetic 
anhydride were used as purchased, without further purification. All reagents were of 
commercial quality and used as received, without further purification. Analytical thin layer 
chromatography (TLC) was performed using plastic-backed pre-coated silica TLC plates 
(Polygram SilG/UV254). Visualisation was achieved by UV irradiation (254 nm) or by 
heating after treatment with a potassium permanganate dip (1.5 g KMnO4, 10 g K2CO3, 
1.25 mL of 10% aqueous NaOH solution and 200 mL of water) or p-anisaldehyde dip (0.7 
mL p-anisaldehyde, 9.5 mL conc. 
H2SO4, 2.7 mL acetic acid and 250 mL of EtOH). The purification of products by 
flash column chromatography was conducted using silica gel 60 (220-240 mesh) with 
the solvent systems indicated. 1H NMR spectra were recorded on either: a Varian 
Unity Inova 500 spectrometer at 500 MHz, or a Varian Inova 300 at 300 MHz. Data are 
listed as follows: chemical shift in ppm using chloroform as internal standard (7.26 ppm) 
or  water (4.79 ppm) or d4-MeOH (3.31), multiplicity (s = singlet, d = doublet, t =triplet, q = 
quartet, m = multiplet or overlap of non-equivalentresonances, br = broad, app. = 
apparent, obs. = (partially) obscured), integration, peak assignment. 13C NMR spectra 
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were recorded on either: a Varian Unity Inova 500 spectrometer at 125 MHz or a Varian 
DirectDrive 600 spectrometer at 150 MHz and the data listed as follows: chemical shift in 
ppm using chloroform as internal standard (77.0 ppm) or d4-MeOH (49.00). The 
assignment of atom connectivity and spatial relationships are exclusively based on 2D 
NMR correlations (NOESY, 1H/1H-COSY, 1H/13C-HMBC and 1H/13C-HSQC). IR bands were 
measured as either a thin film on a Bruker FT-IR Tensor 27 spectrometer with ATR 
sampling accessory or a Bruker ALPHA FT-IR spectrometer as a KBr disc on a Perkin-Elmer 
Spectrum One FT-IR spectrometer. High-resolution mass spectrometry (HRMS) was 
performed on a Agilent 6530 Accurate-Mass Q-TOF LC/MS mass spectrometer with 
Agilent Jet Stream ESI source. Melting points were measured on a Gallenkamp melting 
point apparatus and are uncorrected. Optical rotations were measured on an Autopol II 
polarimeter from Rudolph Research Analytical. The structure of each compound is 
presented with the corresponding method of preparation and spectroscopic data. 
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6.2 Experimental detail for chemical synthesis 
 
 
2-acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose (6) 
 
Sodium acetate (4.18 g, 51.0 mmol) was stirred in acetic anhydride 
(40 mL, 424 mmol) at 100 °C for 5 min, after which time N-acetyl 
glucosamine (8.13g, 36.7mmol) was slowly added over a period of 
10 min and the reaction allowed to stir at 100 °C for an additional 1 h. Water (60 mL) was 
then added to the reaction mixture and the compound extracted with dichloromethane (3 
x 60 mL). The organic layer was then washed with brine (200 mL), dried with anhydrous 
anhydrous MgSO4 and concentrated in vacuo to produce a yellow oil, which was 
recrystallized from methanol to afford the title compound as a white solid (1.46 g, 10%). 
Rf  0.36 (EtOAc). 1HNMR (500 MHz, CDCl3) δ: 5.69 (d, J = 8.5 Hz, 1 H), 5.57 (d, J = 10.0 Hz, 1 
H), 5.14 (m, 2 H), 4.32 (app t, J =  9.5, 1 H), 4.27 (dd, J = 4.5, 12.5 Hz, 1 H), 4.13 (dd, J = 2.0 
Hz, 12.5 Hz, 1 H), 3.81 (m, 1 H), 2.12 (s, 3 H), 2.10 (s, 3 H), 2.05 (s, 3 H), 2.04 (s, 3 H), 1.94 
(s, 3 H). 13CNMR (125 MHz, CDCl3) δ: 171.23, 170.69, 170.07, 169.57, 169.24, 92.61, 72.93, 
72.58, 67.44, 61.62, 53.04, 23.22, 20.91, 20.74, 20.65, 20.60.                                                      
Matched Literature data62   
 
(3aR,5R,6S,7R,7aR)-5-(Acetoxymethyl-6,7-diacetoxy-2-methyl-5,6,7,7a-tetrahydro-3aH-
pyrano[3,2-d]thiazole (7) 
                                                                                                                                                                                               
β-D-Glucosamine pentaacetate (0.370 g, 0.95 mmol) and Lawesson's 
reagent (0.500 g, 1.20 mmol) were stirred in toluene (4 mL) at 90 °C for 3 h, 
after which time the reaction mixture was cooled and concentrated in 
vacuo to afford a yellow oil. The oil was then purified by flash 
chromatography on silica gel (eluent: ethyl acetate/dichloromethane, 3 : 7) 
to give the title compound as a yellow oil (222 mg, 68%). Rf  0.24 (1:3 EtOAc:CH2Cl2).  
1HNMR (500 MHz, CDCl3) δ: 6.24 (d, J = 7.0 Hz, 1 H), 5.57 (dd, J = 1.5, 3.0 Hz, 1 H), 4.95 (d, 
J = 9.5 Hz), 4.48 (s, 1 H), 4.12 (app d, J = 11.0 Hz), 3.53-3.55 (m, 1H), 2.32 (s, 3 H), 2.13 (s, 
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3H), 2.08 (s, 6H). 13CNMR (125 MHz, CDCl3) δ: 170.64, 169.62, 169.34, 168.27, 88.83, 
76.66, 70.72, 69.31, 68.42, 63.30, 20.99, 20.91, 20.78, 20.71.   
Matched Literature data62 
 
2-Acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-β-D-glucopyranoside (8) 
 
GlcNAc-thiazoline triacetate (66 mg, 0.19 mmol) was dissolved in methanol (3.0 mL) and 
cooled to 0 °C. Two drops of TFA and 2 drops of water were then added 
and the reaction stirred for 15 min. The reaction was then removed 
from the ice bath, allowed to warm up to room temperature and 
continued for an additional 2 h, after which time the reaction was concentrated in vacuo 
to afford the title compound as a colourless oil (69 mg, 100%). 1H NMR (500 MHz, CDCl3) 
δ: 5.79 (m, 2 H), 5.13 (t, J = 9.5 Hz, 1 H), 5.09 (t, J = 9.0 Hz, 1 H), 4.32-4.51 (m, 1 H), 4.25-
4.31 (m, 2 H), 4.12 (dd, J = 12.0, 1.5 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 3 H), 2.01 (s, 3 H), and 
1.99 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ: 171.7, 171.4, 170.8, 169.3, 78.5, 70.5, 68.9, 
67.9, 61.7, 52.6, 22.9, 20.6, 20.5.                                                                                                                                                                                                 
Matched literature data74 
 
Cyclohexyl 2-Acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glucopyranoside (9) 
 
Method 1: AIBN (1.8 mg, 0.011 mmol) and thiol 8 (200 mg, 
0.55 mmol) were dissolved in THF (2.2 mL) and cyclohexene 
(0.45 mL, 4.4 mmol) under a nitrogen atomosphere and 
stirred for 1 h, after which time an addition aliquot of 
cyclohexene (0.45 mL, 4.4 mmol)  and AIBN (1.8 mg, 0.011 mmol) were added. The same 
quantity of AIBN and cyclohexene was added each hour, till the reaction had been stirring 
for 4 hours in total. The reaction was then stirred for an additional 1 h, after which time 
AIBN (10.8 mg, 0.066 mmol) was added, the reaction stirred for an hour, and another 
portion of AIBN (10.mg, 0.066) added. The reaction was then allowed to stirred for one 
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more hour, after which time the reaction was cooled and concentrated in vacuo. The 
resulting oil was then purified by flash chromatography on silica (eluent: ethyl acetate : 
dichloromethane 1 : 3) to afford the title compound as a colourless oil, that crystallized 
over time (71 mg, 29%).        
Method 2: α-D-glucosamine pentaacetate 19 (1.01 g, 2.59 mmol) was dissolved in 1,2-
dichloroethane (35 mL). Cyclohexanethiol (1.28 mL, 10.46 mmol) was then added and the 
reaction stirred under nitrogen for 20 min at room temperature. The reaction was then 
cooled to 0 °C and BF3·OEt2 (0.643 mL, 5.21 mmol) added dropwise. The reaction was 
subsequently heated to 55 °C and stirred for 3 h, after which time the reaction was 
quenched with saturated aqueous sodium bicarbonate (35 mL) and extracted into the 
organic phase. The aqueous phase was then washed with additional dichloromethane (2 x 
40 mL). The organic fractions were then combined and washed with saturated brine (100 
mL), dried over anhydrous MgSO4 and concentrated in vacuo. The compound was then 
purified by flash chromatography on silica (eluent: petroleum ether/ethyl acetate, 1 : 2 ) 
to afford the title compound as a white solid (256 mg, 22%). Rf 0.75 (ethyl acetate). M.p. 
119-121 °C.  1H NMR (500 MHz, CDCl3) δ 5.69 (br d, J = 9.2 Hz, 1 H), 5.45 (d, J = 5.2 Hz, 1 
H), 5.09 (t, J = 9.6 Hz, 1 H), 5.02 (t, J = 10 Hz, 1 H), 4.49 (ddd, J = 5.6, 9.2, 10.8 Hz, 1 H), 4.38 
(ddd, J = 2.2, 4.8, 10.0 Hz, 1H), 4.24 (dd, J = 4.8, 12.4 Hz, 1 H), 4.07 (dd, J = 2.4, 12.4 Hz, 1 
H), 2.81 (tt, J = 3.4, 10.2 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 3 H), 2.01(s, 3 H), 1.94 (s, 3 H) , 
1.94–2.10 (m, 2 H), 1.67–1.79 (m, 2 H), 1.54–1.63 (m, 1 H), 1.22–1.42 (m, 5 H). 13C NMR 
(125 MHz, CDCl3) δ 171.1, 170.3, 169.5, 169.0, 83.5, 71.4, 68.3, 68.2, 61.0, 52.1, 44.9, 
34.2, 33.6, 25.9, 25.8, 25.5, 23.2, 20.7 (2 C), 20.6. 
Matched data from literature18    
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2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose (18) 
 
To a solution of D-glucosamine 1  (1.49g, 8.33 mmol) in pyridine (8.3 
mL) was added acetic anhydride (7.8 mL) and the mixture stirred for 18 
h, after which time the mixture was concentrated in vacuo to give a 
yellow/green syrup. Recrystallization of this oil using ethanol yielded the title compound 
as a white powder (1.83g, 4.63 mmol, 56%). 1H NMR (500 MHz, CDCl3) δ: 6.18 (d, J = 3.0 
Hz, 1 H), 5.56 (d, J = 8.5 Hz), 5.17-5.27 (m, 2H), 4.46-4.51 (m, 1H), 4.26 (dd, J = 3.0, 9.0 Hz, 
1H), 4.06 (d, J = 7.5 Hz, 1H), 3.98-4.01 (m, 1H), 2.16 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.01 
(s, 3H), 1.90 (s, 3H). 13C NMR (125 MHz, CDCl3) δ: 171.7, 170.6, 169.9, 169.0, 168.6, 90.6, 
70.6, 69.6, 67.4, 61.4, 51.0.  
 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranose (19) 
 
Glacial acetic acid (0.31 mL, 5.43 mmol) was added to solution of 
ethylenediamine (0.25 mL, 3.81 mmol) in THF (80 mL) and stirred 
under a nitrogen atomosphere for 5 min  at room temperature. α-D-
Glucosamine pentaacetate (1.06 g, 2.72 mmol) was then added to the solution and the 
reaction stirred for 30 h, after which time water (40 mL) was added and the reaction 
extracted into the organic phase. The organic layer was then washed with 10% KHSO4 (40 
mL), saturated aqueous sodium bicarbonate (40 mL) and saturated brine (40 mL), dried 
over anhydrous MgSO4 and concentrated in vacuo. Purification was achieved by flash 
chromatography on silica (eluant: ethyl acetate) to afford the title compound as a white 
soild (666 mg, 70%). Rf 0.33 (ethyl acetate). 1H NMR (500 MHz, CDCl3) δ: 5.98 (d, J = 9.5 
Hz, 1H), 5.30 (t, J = 10.0 Hz, 1 H), 5.25 (d, J = 4.0 Hz, 1 H), 5.12 (t, J = 9.5 Hz, 1 H), 4.28 (td, J 
= 3.0, 9.5 Hz, 1 H), 4.17-4.23 (m, 2 H), 4.09-4.15 (m, 1 H) 2.09 (s, 3H), 2.03 (s, 3H), 2.02 (s, 
3H), 1.96 (s, 3H). 13C NMR (125 MHz, CDCl3) δ: 171.4, 171.0, 170.6, 169.5, 91.4, 71.0, 68.3, 
67.3, 62.1, 52.3, 23.0, 20.7, 20.6 
Matched literature data65 
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2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosyl trichloroacetimidate (20) 
 
Glucosamine tetraacetate 19 (666 mg, 1.92 mmol) was dissolved in 
dichloromethane (15 mL), stirring under a nitrogen atmosphere, and 
subsequently cooled to 0 °C. DBU (0.55 mL, 3.68 mmol) was then 
added, followed by trichloroacetonitrile (0.76 mL, 7.58 mmol). The 
reaction mixture was then stirred for 2 h at 0 °C, after which time the solvent was 
removed in vacuo and the resulting oil purified by flash chromatography on silica (eluant : 
petroleum ether/ethyl acetate, 2 : 1) to afford the title compound as a yellow oil (633 mg, 
67%) Rf  0.71 (ethyl acetate); 1H NMR (300 MHz, CDCl3) δ: 8.80 (s, 1 H), 6.36 (d, J = 3.9 Hz), 
5.60 (d, J = 8.7 Hz), 5.32 (t, J = 9.6 Hz), 5.26 (t, J = 8.7 Hz), 4.41 (td, J = 3.6, 9.3 Hz, 1 H), 
4.55 (dd, J = 3.6, 12.9 Hz, 1 H) 4.11 (m, 2 H), 2.08 (s, 3H), 2.07 (s, 3 H), 2. 06 (s, 3 H), 1.94 
(s, 3 H). 13C NMR (125 MHz, CDCl3) δ: 171.59, 170.62, 169.17, 160.25, 94.74, 70.66, 70.22, 
67.24, 61.41, 51.74, 23.07, 20.74, 20.68, 20.58. 
Matched literature data65 
 
Cyclohexyl 2-Acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-β-D-glucopyranoside (22) 
 
Method 1: Cyclohexanethiol (25 µL, 0.20 mmol) and 
trichloroacetimidate 20 (90 mg, 0.20 mmol) were stirred in 
dichloromethane (1 mL) under a nitrogen atomosphere at  -
42 °C. BF3·OEt2 (2.5 µL, 0.02 mmol) was then added and the reaction stirred for 1 h, after 
which time, the reaction was diluted with dichloromethane (4 mL) quenched with 
saturated aqueous sodium bicarbonate (4 mL) and extracted into the organic layer. The 
aqueous layer was then extracted with additional dichloromethane (2 x 5 mL). The 
combined organic fractions were subsequently washed with saturated brine (15 mL), 
dried over anhydrous MgSO4 and concentrated in vacou. The resulting oil was then 
purified by flash chromatography on silica (eluant: petroleum ether/ethyl acetate ,1 : 2)  
to afford the title compound as a white solid (28 mg, 35%) Rf 0.61 (ethyl acetate) 
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Method 2: α-D-glucosamine pentaacetate 18 (1.01 g, 2.59 mmol) was dissolved in 1,2-
dichloroethane (35 mL). Cyclohexanethiol (1.28 mL, 10.46 mmol) was then added and the 
reaction stirred under nitrogen for 20 minutes at room temperature. The reaction was 
then cooled to 0 °C in a ice salt bath and BF3·OEt2 (0.643 mL, 5.21 mmol) added dropwise. 
The reaction was subsequently heated to 55 °C and stirred for 3 h, after which time the 
reaction was quenched with saturated aqueous sodium bicarbonate (35 mL) and 
extracted into the organic phase. The aqueous phase was then washed with additional 
dichloromethane (2 x 40 mL). The organic fractions were then combined and washed with 
saturated brine (100 mL), dried over anhydrous MgSO4 and concentrated in vacuo. The 
compound was then purified by flash chromatography on silica (eluent:  petroleum 
ether/ethyl acetate,  1 : 2) to afford the title compound as a white solid (128 mg, 11%). Rf 
0.61 (ethyl acetate). 1H NMR (500 MHz, CDCl3) δ: 5.46 (d, J = 9 Hz, 1 H), 5.23 (t, J = 10.2 Hz, 
1 H), 5.07 (t, J = 10.2 Hz, 1 H), 4.76 (d, J = 10.2 Hz, 1 H), 4.21 (dd, J = 5.7, 12.3 Hz, 1 H), 4.12 
(dd, J = 2.4, 12.3 Hz, 1 H), 3.97 (q, J = 9.9 Hz, 1H), 3.69 (ddd, J = 2.79, 5.7, 10.2 Hz, 1 H), 
2.91 (m, 1 H), 2.07 (s, 3H), 2.03 (s, 6 H), 1.95 (m, 5 H) 1.74 (m, 2 H), 1.60 (m, 1 H), 1.15-
1.47 (m, 5 H). 13C NMR (125 MHz, CDCl3) δ: 171.0, 170.6, 170.1, 169.3, 83.6, 75.6, 73.7, 
68.6, 72.5, 53.8, 43.49, 34.0, 26.1, 25.9, 25.6, 23.3, 20.7 (2 C), 20.6. HRMS (ESI): m/z 
C20H32NO8S + [M + H]+ calculated 446.1843, found 446.1846  
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Cyclohexyl 2-(N-tert-butyloxycarbonylacetamido)-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α-D-
glucopyranoside (24) 
 
Thioglycoside 9 (960 mg, 2.15 mmol), DMAP (25.3 mg, 0.207 
mmol) and di-tert-butyl dicarbonate (2.57 g, 11.79 mmol) 
were dissolved in THF (10 mL) and stirred at reflux for 18 h, 
after which time, the reaction mixture was concentrated in 
vacuo. The resulting oil was then purified by flash chromatography on silica (eluent: 
petroleum ether/ethyl acetate, 4 : 1) to afford the title compound as a colorless oil ( 1.18 
g, 100 %). Rf 0.8 (3 : 1 CH2Cl2 : EtOAc). [α]
26
𝐷
 = + 106. IR: 2958, 1742, 1691, 1450, 1368, 
1221, 1148, 1040 cm -1. 1H NMR (500 MHz, CDCl3) δ: 5.93 (app t, J = 10 Hz, 1 H, C-3), 5.44 
(d, J = 5 Hz, 1 H, C-1), 5.03 (br s, 1 H, C-2), 4.94 (t, J = 10 Hz, 1 H, C-4), 4.51 (d, J = 10 Hz, 1 
H, C-5), 4.32 (d, J = 12.5 Hz, 1 H, C-6), 4.07 (d, J = 12.5 Hz, 1 H, C-6'), 2.72 (app t, J = 10 Hz, 
1 H, C-7), 2.41 (s, 3 H, COCH3), 2.08 (s, 3 H, COCH3), 2.01 (s, 3 H, COCH3 ), 1.89-1.98 (m, 5 
H, COCH3 and cy), 1.71, (m, 2 H, cy), 1.49-1.63 (m, 10 H, NHCOOC(CH3)3 and cy), 1.18-1.44 
(m, 5 H, cy). 13C NMR (125 MHz, CDCl3) δ: 173.7 (COCH3), 170.7 (COCH3), 170.1 (COCH3), 
169.5 (COCH3), 152.5 (NHCOOC(CH3)3), 85.2 (NHCOOC(CH3)3)  82.9 (C-1), 70.8 (C-4), 70.7 
(C-3), 67.8 (C-5), 62.2 (C-6), 44.3 (C-7), 34.2 (cy), 33.5 (cy), 27.8 (NHCOOC(CH3)3), 26.9 
(COCH3), 26.0 (cy), 25.8 (cy), 25.6 (cy), 20.8 (COCH3), 20.7 (2 x COCH3). HRMS (ESI): m/z 
C
25
H
40
NO
10
S+ [M + H]+ calculated 546.2367, found 546.2367   
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Cyclohexyl 2-(N-tert-butyloxycarbonylacetamido)-2-deoxy-3,4,6-tri-O-acetyl-1-thio-β-D-
glucopyranoside (25) 
 
Thioglycoside 22 (360 mg, 0.81 mmol), DMAP (13.2 mg, 
0.11 mmol) and di-tert-butyl dicarbonate (955 mg, 4.38 
mmol) were dissolved in THF (4 mL) and refluxed while 
stirring for 18 h. The reaction mixture was subsequently concentrated in vacuo. The 
resulting oil was then purified by flash chromatography on silica (eluent: petroleum 
ether/ethyl acetate, 4 : 1) to afford the title compound as a yellow oil (360 mg, 82 %). Rf 
0.5 (9 : 1, CH2Cl2 : EtOAc). [α]
24
𝐷
 = - 5.2. IR: 2931, 2854, 1739, 1698, 1368, 1235, 1141, 1012 
cm-1.  1H NMR (500 MHz, CDCl3) δ: 5.81 (t, J = 10.0 Hz, 1 H, H-3), 5.70 (t, J = 10.0 Hz, 1 H, 
H'-3), 5.57 (d, J = 10.0 Hz, 1 H, H-1), 5.33 (d, J = 10.0 Hz, 1 H, H'-1), 5.07 (t, J = 10.0 Hz, 1 H, 
H'-4), 5.01 (t, J = 10.0 Hz, 1 H, H-4), 4.90 (t, J = 10.0 Hz, H'-2), 4.22 (m, 3 H, H-2, H-6a and 
H'-6a), 4.09 (t, 10.0 Hz, 2 H, H-6b and H'-6b), 3.76 (m, 1 H, H-5), 3.68 (m, 1 H, H'-5), 2.83 
(m, 2 H, H-7 and H'-7), 2.41 (s, 3 H, COCH3), 2.33 (s, 3 H, COCH3 ), 2.06 (s, 3 H, COCH3 ), 
2.05 (s, 3 H, COCH3 ), 2.00 (s, 6 H, 2 x COCH3), 1.87-1.97 (m, 10 H, 2 x COCH3 and cy), 1.71 
(br s, 4 H, cy), 1.48-1.61 (m, 20 H, 2 x NHCOOC(CH3)3 and cy), 1.15-1.39 (10 H, cy). 13C 
NMR (125 MHz, CDCl3) δ: 173.9 (COCH3), 173.2(COCH3) , 170.7 (2 x COCH3), 170.3 
(COCH3), 170.0 (COCH3),169.7 (COCH3),  169.4 (COCH3), 153.0 (NHCOOC(CH3)3), 151.7 
(NHCOOC(CH3)3), 84.7 (NHCOOC(CH3)3), 84.3 (NHCOOC(CH3)3), 82.7 (C-1') , 82.0 (C-1), 75.7 
(C-5'), 75.4 (C-5), 71.8 (C-3'), 71.4 (C-3), 69.7 (C-4 and C-4'), 62.6 (C-6 and C-6'), 60.5 (C-2), 
55.9 (C-2'), 44.1 (C-7), 43.5 (C'-7), 34.1 (2 x cy), 33.8 (2 x cy), 28.1 (NHCOOC(CH3)3), 27.9 
(NHCOOC(CH3)3), 27.5 (cy), 26.9 (2 x COCH3), 26.1 (cy), 26.0 (cy), 25.9 (2 x cy), 25.6 (2 x cy), 
20.8 (COCH3), 20.7 (3 x COCH3), 20.6 (COCH3), 20.5 (COCH3). HRMS (ESI): m/z C25H40NO10S
+ 
[M + H]+ calculated 546.2367, found 546.2367.  
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Cyclohexyl 2-Amino-2-deoxy-1-thio-α-D-glucopyranoside·HCl (26) 
 
Sodium(33 mg, 1.5 mmol) was added to distilled methanol 
(10 mL) under the presence of a nitrogen atmosphere. Boc-
thioglycoside 24 (990 mg, 1.8 mmol) was subsequently added 
and the reaction stirred at room temperature for 2 hrs, after 
which time concentrated aqueous HCl (2 mL) was added and the reaction stirred for an 
additional 18 h. The compound was then concentrated in vacou to afford the title 
compound as a light yellow solid. This compound was characterized by 1H and 13C NMR 
then a portion of it (5%) carried through to the reaction directly below. 1H NMR (500 MHz, 
D2O) δ: 5.65 (d, 5.5 Hz, 1 H, C-1), 4.08 (m, 1H, C-5), 3.84 (d, J = 12.5 Hz, 1 H, C-6), 3.79 (dd, 
J = 5.0, 12.5 Hz, 1 H, C-6'), 3.68 (t, J = 10.0 Hz, 1 H, C-3), 3.55 (dd, J = 5.0, 11.0 Hz, C-2), 
3.45 (t, J = 9.5 Hz, C-4), 2.98 (m, 1 H, C-7), 1.97 (m, 2 H, cy), 1.71 (m, 2 H, cy), 1.55 (m, 1 H, 
cy), 1.18-1.49 (m, 5 H, cy); 13C NMR (125 MHz, D2O) δ: 81.1 (C-1), 72.7 (C-5), 70.1 (C-3), 
69.8 (C-4), 60.1 (C-6), 53.7 (C-2), 45.0 (C-7), 33.7 (cy), 33.0 (cy), 25.2 (cy), 25.0 (cy). HRMS 
(ESI): m/z C
12
H
24
NO
4
S+ [M + H]+ calculated 278.1421, found 278.1421. 
 
Cyclohexyl 2-Amino-2-N-(N-tert-butylcarbonyl-S-trichlorovinyl -L-cysteinyl)-2-deoxy-1-
thio-α-D-glucopyranoside (11) 
 
α-thioglycoside 26 (31 mga)  and potassium-tert butoxide (11 
mg, 0.098 mmol) were stirred in DMF (0.75 mL) under a 
nitrogen atmosphere. This mixture was subsequently added 
to EDCI (37 mg, 0.193 mmol) and Boc-TCVC (60 mg, 0.239 
mmol) in DMF (0.75 mL), which had been stirring under 
nitrogen at 0 °C for 10 min prior. The reaction was then 
allowed to warm up to room temperature and mixed for 2 h, after which time the DMF 
was concentrated via distillation in vacuo. The reaction mixture was then passed through 
a silica column using a stepwise elution consisting of: petroleum ether; dichloromethane; 
1
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diethyl ether; ethyl acetate and; dichloromethane : methanol (3 : 2) as the eluents. The 
diethyl ether and ethyl acetate fractions were combined and concentrated in vacuu to 
afford a orange solid. Subsequent trituration with chloroform yielded the title compound 
as a white solid (14.5 mg,  26%b) Rf 0.51 (ethyl acetate). M.p. 148 - 149 °C. [α]
27
𝐷
 = + 55. IR: 
3316, 2929, 2855, 1691, 1649, 1546, 1523, 1278 cm-1.  1H NMR (500 MHz, CD3OD) δ: 5.53 
(d, J = 5.0 Hz, 1 H, H-1), 4.30 (m, 1 H, H-8), 3.96 (m, 2 H, H-2 and H-5), 3.79 (d, J = 12.0 Hz, 
1 H, H-6), 3.72 (dd, J = 5.0, 12.0 Hz, 1H, H-6'), 3.51 (t, J = 9.5 Hz, 1 H, H-3), 3.44 (dd, J = 5.0, 
14.0 Hz, 1 H, H-9), 3.35 (t, J = 9.5 Hz, 1 H, H-4), 3.14 (dd, J = 9.5, 14 Hz, 1 H, H-9'), 2.81 (m, 
1 H, H -12), 1.98 (m, 2 H, cy), 1.74 (m, 2 H, cy), 1.59 (m, 1 H, cy), 1.47 (m, 9 H, 
NHCOOC(CH3)3), 1.21-1.43 (m, 5 H, cy). 13C NMR (125 MHz, CD3OD) δ:  171.15 (C-7), 
156.15 (NHCOOC(CH3)3), 127.07 (C-11 or C-12), 121.07 (C-11 or C-12), 82.70 (C-1), 79.63 
(NHCOOC(CH3)3), 73.13 (C-5), 71.59 (C-3), 71.02 (C-4), 61.11 (C-6), 54.55 (C-2), 54.05 (C-8), 
43.73 (C-12), 35.33 (C-9), 33.98 (cy), 33.59 (cy), 27.37 (NHCOO(CH3)3), 25.69 (cy), 25.53 
(cy), 25.47 (cy). HRMS (ESI): C
22
H
36
Cl
3
N
2
O
7
S
2
+ [M + H]+ calculated 609.1024 found 
609.1036. 
 a5%, by weight, of compound 26 synthesized above. bCalculated over two steps starting 
from 24 
 
Cyclohexyl 2-Amino-2-deoxy-1-thio-β-D-glucopyranoside·HCl (27) 
 
Sodium (12 mg, 0.55 mmol) was added to distilled 
methanol (1.6 mL) under the presence of a nitrogen 
atmosphere. Boc-thioglycoside 25 (342 mg, 0.63 mmol) was 
subsequently added and the reaction stirred at room 
temperature for 2 h, after which time concentrated aqueous HCl (0.8 mL) was added and 
the reaction stirred for an additional 18 h. The compound was then concentrated in vacuo 
to afford the title compound as a light yellow solid. This compound was characterized by 
1H and 13C NMR then a portion of it (32%) carried through to the reaction directly below.  
1H NMR (500 MHz, D2O) δ: 4.90 (d, J = 10.5 Hz, 1 H, H-1), 3.90 (d, J = 12.0 Hz, 1 H, C-6), 
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3.73 (br d, J = 11.0 Hz, 1 H, C-6'), 3.68 (t, J = 9.0 Hz, 1 H, C-3), 3.51 (m, 2 H, C-4 and C-5), 
3.14 (t, J = 11.0 Hz, 1 H, C-2), 3.08 (m, 1 H, C-7), 1.99 (br s, 2 H), 1.74 (m, 2 H), 1.59 (m, 1 
H), 1.19-1.51 (m, 5 H). 13C NMR (125 MHz, D2O) δ: 80.8 (C-1), 79.9 (C-5), 73.5 (C-3), 69.5, 
60.5 (C-4), 55.1 (C-2), 44.6 (C-7), 33.7 (cy), 33.4 (cy), 25.5 (cy), 25.4 (cy), 24.9 (cy).  HRMS 
(ESI): m/z C
12
H
24
NO
4
S+ [M + H]+ calculated 278.1421, found 278.1420. 
 
Cyclohexyl 2-Amino-2-N-(N-tert-butylcarbonyl-S-trichlorovinyl -L-cysteinyl)-2-deoxy-1-
thio-β-D-glucopyranoside (28) 
 
β-thioglycoside 27 (67 mga) of and potassium-tert butoxide 
(25 mg, 0.22 mmol) were stirred in DMF (2 mL) under a 
nitrogen atomoshpere. This mixture was subsequently 
added to EDCI (84 mg, 0.54 mmol) and Boc-TCVC (119 mg, 
0.33 mmol) in DMF (2 mL), which had been stirring under 
nitrogen at 0 ° C for 10 min prior. The reaction was then 
allowed to warm up to room temperature and mixed for 2 h,  after which time the DMF 
was concentrated via distillation in vacuo. The reaction mixture was then passed through 
a silica column using a stepwise elution consisting of: petroleum ether; dichloromethane; 
diethyl ether; ethyl acetate; and dichloromethane : methanol (3 : 2) as the eluents. The 
diethyl ether and ethyl acetate fractions were combined and concentrated in vacuo to 
afford an orange solid. Subsequent trituration with chloroform yielded the title compound 
as a white solid (43.1 mg, 35%b) Rf  0.30 (ethyl acetate). M.p. 195-197 °C (degraded). [α]
23
𝐷
 
= - 2.89. IR: 3316, 2930, 2854, 1690, 1654, 1541, 1529, 1205, 1141 cm-1. 1H NMR (500 
MHz, CD3OD) δ: 4.73 (d, J = 10 Hz, 1 H, H-1), 4.27 (dd, J = 4.5, 8.5 Hz, 1 H, H-8), 3.85 (d, J = 
12 Hz, 1 H, H-6), 3.67 (dd, J = 7.0, 12.0 Hz, 1 H, H-6'), 3.56 (m, 2 H,  H-2 and H-3), 3.48 (dd, 
4.5, 14 Hz, H-9), 3.25-3.37 (m, 2 H, H-4 and H-5), 3.13 (dd, 8.5, 14 Hz, H-9'), 2.93 (m, 1 H, 
H-12), 2.00 (m, 1 H, cy), 1.93 (m, 1H, cy), 1.73 (m, 2 H, cy), 1.59 (m, 1 H, cy), 1.45 (s, 9 H, 
NHCOOC(CH3)3), 1.17-1.39 (m, 5 H, cy). 13C NMR (125 MHz, CD3OD) δ: 170.9 (C-7), 156.1 
(NHCOOC(CH3)3), 127.2 (C-10 or C-11), 120.9 (C-10 or C-11), 83.0 (C-1), 80.4 
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(NHCOOC(CH3)3), 79.9 (C-5), 75.25 (C-3), 70.62 (C-3), 61.62 (C-6), 55.78 (C-2), 54.33 (C-8), 
42.88 (C-12), 35.93 (C-9), 33.96 (cy), 33.77 (cy), 27.67 (NHCOOC(CH3)3), 25.81 (cy), 25.63 
(cy), 25.53 (cy). HRMS (ESI): m/z C
22
H
36
Cl
3
N
2
O
7
S
2
+ [M + H]+ calculated 609.1024 found 
609.1032. 
 a32%, by weight, of compound 27 that synthesized above).bCalculated over two steps 
starting from 25                                           
Cyclohexyl 2-Amino-2-N-(S-trichlorovinyl -L-cysteinyl)-2-deoxy-1-thio-α-D-
glucopyranoside·Trifluoroacetic acid (13) 
 
Anhydrous TFA (1 mL) was cooled to 0 °C and added to β-N-
Boc-TCVC thoglycoside 28 (9.5 mg, 0.014 mmol). The 
reaction was stirred at 0 °C for 5 min, after which time the 
reaction was warmed  up to room temperature over a 20 
min period. The reaction was then concentrated to afford 
an orange oil. The compound was then triturated with 
chloroform to afford the title compound an orange oil (3 mg, 35%) Rf  0.52 (19 : 1, EtOAc : 
Methanol). [α]26
𝐷
 = + 77. IR: 3350, 2999, 2845, 1672, 1563, 1448, 1201, 1092 cm-1. 1H NMR 
(500 MHz, CD3OD) δ: 5.56 (d, J = 5.0 Hz, 1H, C-1), 3.95-4.11 (m, 3 H, H-2, H-5 and H-8), 
3.80 (dd, J = 2.4, 12.5 Hz, 1 H, H-6), 3.73 (dd, J = 6.5, 12 Hz, 1 H, H6'), 3.59 (m, 2 H, H9' and 
H-3), 3.36 (t, J = 10 Hz, 1 H, H-4), 3.32 (obs m, 1 H, H-9'), 2.84, (m, 1 H), 1.99 (m, 2 H), 1.74 
(m, 2 H), 1.60 (m, 1 H), 1.22-1.44 (m, 5H). 13C NMR (125 MHz, CD3OD) δ: 166.6 (C-7), 125.3 
(C-10 or C-11), 123.2 (C-10 or C-11), 82.5 (C-1), 72.9 (C-5), 71.3 (C-3 and C-4), 61.0 (C-6), 
54.8 (C-2), 52.2 (C-8), 43.5 (C-12), 35.2 (cy), 34.0 (cy), 33.4 (cy), 25.7 (cy), 25.6 (cy), 25.5 
(cy). HRMS (ESI): m/z C
17
H
28
Cl
3
N
2
O
5
S
2
+ [M + H]+ calculated 509.0500 found 509.0495.  
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Cyclohexyl 2-Amino-2-N-(S-trichlorovinyl -L-cysteinyl)-2-deoxy-1-thio-β-D-
glucopyranoside·Trifluoroacetic acid (29)  
  
Anhydrous TFA (2 mL) was cooled to 0 °C and added to β-N-Boc-
TVCV thioglycoside 28 (20.4 mg, 0.033 mmol). The reaction was 
stirred at 0 °C for 5 min, after which time the reaction was 
warmed  up to room temperature over a 20 min period. The 
reaction was then concentrated to afford the title compound as an orange oil (21mg, 
100%) 1H NMR (500 MHz, CD3OD) δ: 4.82 (obs d, J = 11.5 Hz, 1 - H), 4.03 (m, 1 H), 3.86 (d, 
J = 12 Hz, 1 H), 3.58-3.71 (m, 3 H), 3.54 (t, J = 10 Hz, 1 H), 3.25-3.38 (obs, 3H), 3.00 (br s, 1 
H), 2.00 (m, 2 H), 1.20-1.74 (obs by degradation product, 8 H). 13C NMR (125 Hz, CD3OD) 
δ: 166.6, 125.3, 82.3, 80.7, 75.4, 70.8, 61.4, 56.3, 52.5, 42.7, 35.3, 34.0, 33.8, 25.7, 25.5 (2 
C). HRMS (ESI): m/z C
17
H
28
Cl
3
N
2
O
5
S
2
+ [M + H]+ calculated 509.0500 found 509.0508. 
 
N-Boc-L-Cystine (15) 
L-cystine (2.12 g, 8.88 mmol) was dissolved sodium hydroxide 
(0.5 M, 25 mL). Subsequently, di-tert-butyl dicarbonate (4.30 
g, 19.7 mmol) in THF (7.6 mL) was added slowly over a period 
of 30 min. The reaction was then stirred for 18 hr, after which time, ethyl acetate (40 mL) 
was added and the reaction cooled in an ice-salt bath to 0 °C. The pH was then dropped to 
approximately 2 using HCl (1 M) and the organic layer seperated.  The organic layer was 
subsequently washed with saturated brine, dried over Anhydrous MgSO and concentrated 
to afford the title compound as a white solid (3.51 g, 93%) Rf  0.68 (3 : 1 CH2Cl2 : EtOAc). 
1H NMR (500 MHz, CDCl3) δ: 5.56 (d, J = 8.5 Hz, 1 H), 4.77 (br s, 1 H), 3.31 (d, J = 10 Hz, 1 
H), 3.20 (d, J = 10 Hz, 1 H).  
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N-Boc-L-Cysteine (2) 
Method 1: N-Boc-cystine  (270 mg, 0.62 mmol) was dissolved in 5% 
glacial acetic acid in THF (10 mL) at 0 ºC, Zinc dust (2.27 g) was 
added slowly over a period of 20 min. The reaction was then 
allowed to warm to room temperature over a 1 h period and left 
stirring for an additional 3 h. The reaction was then filtered through celite and washed 
with glacial acetic acid. The filtrate was subsequently concentrated in vacuo and the 
resulting residue taken up in 1M HCl (8 mL) the aqueous phase was extracted with 
ethylacetate (8 mL), washed with saturated brine and dried over Anhydrous MgSO. The 
organic was then concentrated in vacuo to produce the title compound as a colourless oil 
(131 mg, 97%) 
Method 2: L-Cysteine hydrochloride monohydrate (2.09 g, 11.9 mmol), sodium 
bicarbonate (1.96 g, 23.3 mmol) and di-tert-butyl dicarbonate (654 mg, 3.0 mmol) were 
placed in a round bottom flask under a nitrogen atmosphere. In two additional, separate, 
round bottom flasks, water (50 mL) and THF (10 mL) were bubbled through with nitrogen 
for 30 min each. Aliquots of 43 mL and 3 mL of water and THF respectively, were added to 
the flask containing the L-cysteine hydrochloride monohydrate, sodium bicarbonate)and 
di-tert-butyl dicarbonate and the reaction stirred at room temperature for 18 h. Ethyl 
acetate (50 mL) was then added and the reaction acidified to pH 3 using H2SO4 (1 M). The 
organic layer was then washed with saturated  brine, dried over Anhydrous MgSO and 
concentrated to afford the title compound as a colorless oil (440 mg, 66%) Rf 0.68 (3 : 1 
CH2Cl2 : EtOAc) 1H NMR (500 MHz, CDCl3) δ:  5.47 ( app d, J = 6.5 Hz, 1 H), 4.65 (br s, 1 H), 
2.95-3.10 (m, 2 H).  
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N-Boc-S-triclorovinyl Cysteine (3) 
N-Boc-L-cysteine 2 (440 mg, 1.25 mmol)  was dissolved in 
tetrachloroethylene (10 mL, 97.6 mmol) and acetonitrile 
(6.4 mL). The reaction mixture was then stirred under a 
nitrogen atmosphere for 45 min, after which time DBN (0.64 mL, 5.18 mmol) was added 
dropwise and the reaction allowed to stir for an additional 30 min. Dichloromethane (50 
mL) and water (20 mL) was then added and the reaction mixture acidified to 
approximately pH 2 using H2SO4 (1 M). The organic layer was then extracted, washed with 
brine, dried over Anhydrous MgSO and concentrated in vacuo to afford the title 
compound as a colourless oil (480 mg, 69%). 1H NMR (500 MHz, CDCl3) δ: 5.35 (d, J = 7 
Hz), 4.66 (d, J = 6 Hz),  3.56 (dd, J = 3.5, 14.5 Hz), 3.36 (dd, J = 4.5 Hz, 14.5 Hz), 1.46 (s, 9 H). 
13C NMR (125 MHz, CDCl3) δ: 174.35, 155.03, 126.76, 122.49, 80.92, 53.62, 35.80, 28.28 
 
6.3 Experimental Details for Macromodel Calculations 
 
Lowest energy conformers of the compounds studied were obtained by molecular 
mechanics and methodology.  Each structure was subjected to exhaustive conformational 
searching using the mixed torsional/low mode sampling routine as implemented in 
MacroModel version 9.7 (Mohamadi, 1990)101 and visualised in Maestro 9.0.  The 
simulation was continued until the five lowest energy structures reported had been 
replicated at least 25 times.  Structures obtained were minimized using the OPLS_2005 
forcefield using the chloroform model (Still, 1990) and the Polak–Ribiere conjugate 
gradient (PRCG) conjugate gradients method and terminated on a gradient threshold of 
0.01 kJ mol-1Å-1.  
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6.4 Experimental Detail for MTT Cell Proliferation Assay 
 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium) and the solubilizer were 
prepared according to Berridge et al. (1996). An HL60 cell suspension (1 x 106 cells/mL) 
was added to 2-fold dilutions of the compounds in RPMI 1640 in sterile 96-well plates, 
giving final concentrations ranging from250 to 1.2 µM. The volume was brought up to 100 
µL with RPMI 1640. Cells were incubated for either for 24 h at 37°C. After the incubation, 
MTT (20 µl per well) was added and allowed to react for 2 h at 37°C, solubilizer (200 µl per 
well) was added and the plates incubated overnight at 37°C. The absorbance was read in a 
microplate reader at 570 nm102. 
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Appendix 
 
 
1H NMR and 13C NMR spectrum of 11 
86 
 
 
 
1H NMR and 13C NMR spectrum of 27 
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1H NMR and 13C NMR spectrum of 13 
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1H NMR (CDCl3/TFA)(Top) and 1H NMR (MeOD)(Bottom) spectrum of 28 
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